10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)
☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended October 1, 2023

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                      to                    .

Commission file number 1-5353

TELEFLEX INCORPORATED

(Exact name of registrant as specified in its charter)

Delaware	23-1147939
(State or other jurisdiction of incorporation or organization)	(I.R.S. employer identification no.)

550 E. Swedesford Rd., Suite 400 Wayne, PA 19087

(Address of principal executive offices and zip code)

(610) 225-6800

(Registrant’s telephone number, including area code)

(None)

(Former Name, Former Address and Former Fiscal Year,

If Changed Since Last Report)

Securities registered pursuant to Section 12(b) of the Act:
	Title of each class	Trading Symbol(s)	Name of each exchange on which registered
	Common Stock, par value $1.00 per share	TFX	New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     Yes   ☒    No  ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☒	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☐
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).   Yes  ☐    No  ☒

The registrant had 46,992,664 shares of common stock, par value $1.00 per share, outstanding as of October 31, 2023 .

TELEFLEX INCORPORATED

QUARTERLY REPORT ON FORM 10-Q

FOR THE QUARTER ENDED OCTOBER 1, 2023

TABLE OF CONTENTS

		Page
PART I — FINANCIAL INFORMATION
Item 1:	Financial Statements (Unaudited):	2
	Condensed Consolidated Statements of Income	2
	Condensed Consolidated Statements of Comprehensive Income	3
	Condensed Consolidated Balance Sheets	4
	Condensed Consolidated Statements of Cash Flows	5
	Condensed Consolidated Statements of Changes in Equity	6
	Notes to Condensed Consolidated Financial Statements	7
Item 2:	Management’s Discussion and Analysis of Financial Condition and Results of Operations	19
Item 3:	Quantitative and Qualitative Disclosures About Market Risk	26
Item 4:	Controls and Procedures	26
PART II — OTHER INFORMATION
Item 1:	Legal Proceedings	28
Item 1A:	Risk Factors	28
Item 2:	Unregistered Sales of Equity Securities and Use of Proceeds	28
Item 3:	Defaults Upon Senior Securities	28
Item 4:	Mine Safety Disclosures	28
Item 5:	Other Information	28
Item 6:	Exhibits	29
SIGNATURES		30

1

PART I — FINANCIAL INFORMATION

Item 1. Financial Statements

TELEFLEX INCORPORATED

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(Unaudited)

	Three Months Ended				Nine Months Ended
	October 1, 2023		September 25, 2022		October 1, 2023		September 25, 2022
	(Dollars and shares in thousands, except per share)
Net revenues	$	746,389	$	686,788	$	2,200,580	$	2,033,045
Cost of goods sold	330,078		312,833		985,066		924,024
Gross profit	416,311		373,955		1,215,514		1,109,021
Selling, general and administrative expenses	213,194		209,616		669,216		630,373
Research and development expenses	37,576		37,770		118,493		111,064
Restructuring and impairment charges	231		628		3,960		2,950
Gains on sale of asset and business	—		(6,504)		—		(6,504)
Income from continuing operations before interest and taxes	165,310		132,445		423,845		371,138
Interest expense	23,192		13,375		59,291		35,212
Interest income	(7,487)		(126)		(9,486)		(577)
Income from continuing operations before taxes	149,605		119,196		374,040		336,503
Taxes on income from continuing operations	11,935		17,315		47,651		51,700
Income from continuing operations	137,670		101,881		326,389		284,803
Operating (loss) income from discontinued operations	(687)		19		(1,512)		(329)
Tax (benefit) expense on operating loss from discontinued operations	(157)		5		(346)		(76)
(Loss) income from discontinued operations	(530)		14		(1,166)		(253)
Net income	$	137,140	$	101,895	$	325,223	$	284,550
Earnings per share:
Basic:
Income from continuing operations	$	2.93	$	2.17	$	6.95	$	6.07
Loss from discontinued operations	(0.01)		—		(0.03)		—
Net income	$	2.92	$	2.17	$	6.92	$	6.07
Diluted:
Income from continuing operations	$	2.91	$	2.16	$	6.90	$	6.02
Loss from discontinued operations	(0.01)		—		(0.02)		(0.01)
Net income	$	2.90	$	2.16	$	6.88	$	6.01
Weighted average common shares outstanding
Basic	46,992		46,906		46,974		46,894
Diluted	47,299		47,263		47,304		47,337

The accompanying notes are an integral part of the condensed consolidated financial statements.

2

TELEFLEX INCORPORATED

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(Unaudited)

 

	Three Months Ended				Nine Months Ended
	October 1, 2023		September 25, 2022		October 1, 2023		September 25, 2022
	(Dollars in thousands)
Net income	$	137,140	$	101,895	$	325,223	$	284,550
Other comprehensive (loss) income, net of tax:
Foreign currency translation, net of tax of $(4,667), $(12,477), $(434), and $(20,300) for the three and nine months periods, respectively	(29,417)		(55,194)		(13,368)		(123,576)
Pension and other postretirement benefit plans adjustment, net of tax of $(476), $(716), $(1,182), and $(1,862) for the three and nine months periods, respectively	1,543		2,195		3,951		5,807
Derivatives qualifying as hedges, net of tax of $(116), $(196), $334, and $(330) for the three and nine months periods, respectively	(2,412)		2,502		789		5,536
Other comprehensive (loss) income, net of tax:	(30,286)		(50,497)		(8,628)		(112,233)
Comprehensive income	$	106,854	$	51,398	$	316,595	$	172,317

The accompanying notes are an integral part of the condensed consolidated financial statements.

3

TELEFLEX INCORPORATED

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

	October 1, 2023		December 31, 2022
	(Dollars in thousands)
ASSETS
Current assets
Cash and cash equivalents	$	881,499	$	292,034
Accounts receivable, net	425,194		408,834
Inventories	625,075		578,507
Prepaid expenses and other current assets	138,657		125,084
Prepaid taxes	26,846		6,524
Total current assets	2,097,271		1,410,983
Property, plant and equipment, net	464,467		447,205
Operating lease assets	123,604		131,211
Goodwill	2,528,305		2,536,730
Intangible assets, net	2,180,539		2,306,165
Deferred tax assets	6,167		6,402
Other assets	93,281		89,367
Total assets	$	7,493,634	$	6,928,063
LIABILITIES AND EQUITY
Current liabilities
Current borrowings	$	87,500	$	87,500
Accounts payable	130,686		126,807
Accrued expenses	133,067		140,644
Payroll and benefit-related liabilities	127,101		133,092
Accrued interest	17,428		5,332
Income taxes payable	24,375		24,736
Other current liabilities	65,265		63,381
Total current liabilities	585,422		581,492
Long-term borrowings	1,950,123		1,624,023
Deferred tax liabilities	389,080		388,886
Pension and postretirement benefit liabilities	30,051		31,394
Noncurrent liability for uncertain tax positions	6,545		5,805
Noncurrent operating lease liabilities	111,810		120,437
Other liabilities	106,555		154,058
Total liabilities	3,179,586		2,906,095
Commitments and contingencies
Total shareholders' equity	4,314,048		4,021,968
Total liabilities and shareholders' equity	$	7,493,634	$	6,928,063

The accompanying notes are an integral part of the condensed consolidated financial statements.

4

TELEFLEX INCORPORATED

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

	Nine Months Ended
	October 1, 2023		September 25, 2022
	(Dollars in thousands)
Cash flows from operating activities of continuing operations:
Net income	$	325,223	$	284,550
Adjustments to reconcile net income to net cash provided by operating activities:
Loss from discontinued operations	1,166		253
Depreciation expense	52,687		49,076
Intangible asset amortization expense	125,230		121,904
Deferred financing costs and debt discount amortization expense	2,547		3,150
Changes in contingent consideration	(24,482)		237
Assets impairment charges	—		1,497
Stock-based compensation	22,135		19,804
Gain on sale of business	—		(6,504)
Deferred income taxes, net	2,076		63
Payments for contingent consideration	(289)		(2,983)
Interest benefit on swaps designated as net investment hedges	(15,459)		(15,677)
Other	4,743		(3,953)
Changes in assets and liabilities, net of effects of acquisitions and disposals:
Accounts receivable	(18,313)		(36,402)
Inventories	(50,702)		(85,293)
Prepaid expenses and other assets	7,487		21,298
Accounts payable, accrued expenses and other liabilities	(16,674)		(26,726)
Income taxes receivable and payable, net	(45,014)		(79,879)
Net cash provided by operating activities from continuing operations	372,361		244,415
Cash flows from investing activities of continuing operations:
Expenditures for property, plant and equipment	(63,768)		(52,648)
Proceeds from sale of business and assets	—		12,434
Payments for businesses and intangibles acquired, net of cash acquired	(205)		(27,308)
Net interest proceeds on swaps designated as net investment hedges	10,275		10,314
Proceeds from sales of investments	7,300		7,300
Purchase of investments	(11,300)		(7,300)
Net cash used in investing activities from continuing operations	(57,698)		(57,208)
Cash flows from financing activities of continuing operations:
Proceeds from new borrowings	646,000		—
Reduction in borrowings	(321,625)		(144,250)
Net proceeds (payments) from share based compensation plans and related tax impacts	534		(4,398)
Payments for contingent consideration	(949)		(3,885)
Dividends paid	(47,919)		(47,840)
Net cash provided by (used in) financing activities from continuing operations	276,041		(200,373)
Cash flows from discontinued operations:
Net cash used in operating activities	(579)		(482)
Net cash used in discontinued operations	(579)		(482)
Effect of exchange rate changes on cash and cash equivalents	(660)		(34,177)
Net increase (decrease) in cash and cash equivalents	589,465		(47,825)
Cash and cash equivalents at the beginning of the period	292,034		445,084
Cash and cash equivalents at the end of the period	$	881,499	$	397,259

The accompanying notes are an integral part of the condensed consolidated financial statements.

5

TELEFLEX INCORPORATED

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

(Unaudited)

	Common Stock			Additional Paid In Capital		Retained Earnings		Accumulated Other Comprehensive Loss		Treasury Stock			Total
	Shares	Dollars								Shares	Dollars
	(Dollars and shares in thousands, except per share)
Balance at December 31, 2022	47,957	$	47,957	$	715,118	$	3,817,304	$	(403,522)	1,032	$	(154,889)	$	4,021,968
Net income						76,748							76,748
Cash dividends ($0.34 per share)						(15,969)							(15,969)
Other comprehensive income								22,191					22,191
Shares issued under compensation plans	18	18		2,333						(19)	2,639		4,990
Deferred compensation	—	—		324						(6)	1		325
Balance at April 2, 2023	47,975	47,975		717,775		3,878,083		(381,331)		1,007	(152,249)		4,110,253
Net income						111,335							111,335
Cash dividends ($0.34 per share)						(15,972)							(15,972)
Other comprehensive loss								(533)					(533)
Shares issued under compensation plans	23	23		9,920						—	66		10,009
Balance at July 2, 2023	47,998	47,998		727,695		3,973,446		(381,864)		1,007	(152,183)		4,215,092
Net income						137,140							137,140
Cash dividends ($0.34 per share)						(15,978)							(15,978)
Other comprehensive loss								(30,286)					(30,286)
Shares issued under compensation plans	1	1		8,057						(1)	22		8,080
Balance at October 1, 2023	47,999	$	47,999	$	735,752	$	4,094,608	$	(412,150)	1,006	$	(152,161)	$	4,314,048

	Common Stock			Additional Paid In Capital		Retained Earnings		Accumulated Other Comprehensive Loss		Treasury Stock			Total
	Shares	Dollars								Shares	Dollars
	(Dollars and shares in thousands, except per share)
Balance at December 31, 2021	47,929	$	47,929	$	693,090	$	3,517,954	$	(346,959)	1,069	$	(157,266)	$	3,754,748
Net income						77,141							77,141
Cash dividends ($0.34 per share)						(15,946)							(15,946)
Other comprehensive loss								(21,286)					(21,286)
Shares issued under compensation plans	5	5		(950)						(27)	894		(51)
Deferred compensation	—	—		100						(5)	828		928
Balance at March 27, 2022	47,934	47,934		692,240		3,579,149		(368,245)		1,037	(155,544)		3,795,534
Net income						105,514							105,514
Cash dividends ($0.34 per share)						(15,946)							(15,946)
Other comprehensive loss								(40,450)					(40,450)
Shares issued under compensation plans	6	6		7,918						(2)	151		8,075
Deferred compensation	—	—		(2)						—	5		3
Balance at June 26, 2022	47,940	47,940		700,156		3,668,717		$	(408,695)	1,035	(155,388)		3,852,730
Net income						101,895							101,895
Cash dividends ($0.34 per share)						(15,948)							(15,948)
Other comprehensive loss								(50,497)					(50,497)
Shares issued under compensation plans	1	1		6,904						(1)	76		6,981
Balance at September 25, 2022	47,941	$	47,941	$	707,060	$	3,754,664	$	(459,192)	1,034	$	(155,312)	$	3,895,161

The accompanying notes are an integral part of the condensed consolidated financial statements.

6

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

 (all tabular amounts in thousands unless otherwise noted)

Note 1 — Basis of presentation

The accompanying unaudited condensed consolidated financial statements of Teleflex Incorporated and its subsidiaries (“we,” “us,” “our" and “Teleflex”) are prepared on the same basis as its annual consolidated financial statements.

In the opinion of management, the financial statements reflect all adjustments, which are of a normal recurring nature, necessary for the fair statement of the financial statements for interim periods in accordance with accounting principles generally accepted in the United States of America ("GAAP") and Rule 10-01 of Securities and Exchange Commission ("SEC") Regulation S-X, which sets forth the instructions for the form and content of presentation of financial statements included in Form 10-Q. The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The results of operations for the periods reported are not necessarily indicative of those that may be expected for a full year.

In accordance with applicable accounting standards and as permitted by Rule 10-01 of Regulation S-X, the accompanying condensed consolidated financial statements do not include all of the information and footnote disclosures that are required to be included in our annual consolidated financial statements. Therefore, our quarterly condensed consolidated financial statements should be read in conjunction with our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2022.

Note 2 — Recently issued accounting standards

From time to time, new accounting guidance is issued by the FASB or other standard setting bodies that is adopted by us as of the effective date or, in some cases where early adoption is permitted, in advance of the effective date. We have assessed the recently issued guidance that is not yet effective and believe the new guidance will not have a material impact on the consolidated results of operations, cash flows or financial position.

Note 3 — Net revenues

We primarily generate revenue from the sale of medical devices including single use disposable devices and, to a lesser extent, reusable devices, instruments and capital equipment. Revenue is recognized when obligations under the terms of a contract with our customer are satisfied; this occurs upon the transfer of control of the products. Generally, transfer of control to the customer occurs at the point in time when our products are shipped from the manufacturing or distribution facility. For our Original Equipment and Development Services ("OEM") segment, most revenue is recognized over time because the OEM segment generates revenue from the sale of custom products that have no alternative use and we have an enforceable right to payment to the extent that performance has been completed. We market and sell products through our direct sales force and distributors to customers within the following end markets: (1) hospitals and healthcare providers; (2) other medical device manufacturers; and (3) home care providers, which constituted 87%, 11% and 2% of consolidated net revenues, respectively, for the nine months ended October 1, 2023. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring goods. With respect to the custom products sold in the OEM segment, revenue is measured using the units produced output method. Payment is generally due 30 days from the date of invoice.

7

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

The following table disaggregates revenue by global product category for the three and nine months ended October 1, 2023 and September 25, 2022.

	Three Months Ended				Nine Months Ended
	October 1, 2023		September 25, 2022		October 1, 2023		September 25, 2022
Vascular access	$	169,919	$	167,147	$	521,356	$	497,188
Anesthesia	97,612		97,608		291,786		289,260
Interventional	134,089		108,738		375,766		319,939
Surgical	112,805		93,124		317,781		282,468
Interventional urology	73,622		78,969		226,819		233,682
OEM	82,309		71,288		243,434		198,947
Other (1)	76,033		69,914		223,638		211,561
Net revenues (2)	$	746,389	$	686,788	$	2,200,580	$	2,033,045

(1)    Includes revenues generated from sales of our respiratory and urology products (other than interventional urology products).

(2)    The product categories listed above are presented on a global basis, while each of our reportable segments other than the OEM reportable segment are defined based on the geographic location of its operations; the OEM reportable segment operates globally. Each of the geographically based reportable segments includes net revenues from each of the non-OEM product categories listed above.

Note 4 — Acquisitions and Divestiture

2023 acquisition

On July 25, 2023, we executed a definitive agreement to acquire Palette Life Sciences AB (“Palette”), a privately held medical device company that sells a portfolio of hyaluronic acid gel-based products primarily utilized in the treatment of urology diseases including a rectal spacing product used in connection with radiation therapy treatment of prostate cancer. The acquisition will complement our interventional urology product portfolio. On October 10, 2023, we completed the acquisition of Palette using borrowings under our revolving credit facility and cash on hand. Under the terms of the agreement, we acquired Palette for an initial cash payment of $600 million, with additional consideration of up to $50 million payable upon the achievement of certain commercial milestones.

2022 acquisition

In the fourth quarter of 2022, we completed the acquisition of Standard Bariatrics, Inc. (“Standard Bariatrics”), a privately-held medical device company that commercialized a powered stapling technology for bariatric surgery that complements our surgical product portfolio. Under the terms of the agreement, we acquired Standard Bariatrics for cash payments of $173 million, with the potential to make three milestone payments up to $130 million in the aggregate if certain commercial milestones are met.

Divestiture

On May 15, 2021, we entered into a definitive agreement to sell certain product lines within our global respiratory product portfolio (the "Divested respiratory business") to Medline Industries, Inc. (“Medline”) for consideration of $286.0 million, reduced by $12 million in working capital not transferring to Medline, which is subject to customary post close adjustments (the "Respiratory business divestiture"). In connection with the Respiratory business divestiture, we also entered into several ancillary agreements with Medline to help facilitate the transfer of the business, which provide for transition support, quality, supply and manufacturing services, including a manufacturing and supply transition agreement (the "MSTA").

On June 28, 2021, the first day of the third quarter of 2021, we completed the initial phase of the Respiratory business divestiture, pursuant to which we received cash proceeds of $259 million. The second phase of the Respiratory business divestiture will occur once we transfer certain additional manufacturing assets to Medline and is expected to occur prior to the end of 2023. We plan to recognize the remaining consideration, and any gain on sale resulting from the completion of the second phase of the divestiture, when it becomes realizable.

8

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

Net revenues attributed to services provided to Medline in accordance with the MSTA, which are presented within our Americas reporting segment, were $21.7 million and $62.7 million for the three and nine months ended October 1, 2023, respectively, and $19.1 million and $60.5 million for the three and nine months ended September 25, 2022, respectively.

Note 5 — Restructuring and impairment charges

Restructuring and impairment charges recognized for the three and nine months ended October 1, 2023 and September 25, 2022 consisted of the following:

Three Months Ended October 1, 2023	Termination Benefits		Other Costs (1)		Total
2023 Footprint realignment plan	$	1,296	$	—	$	1,296
2022 Restructuring plan	244		102		346
Respiratory divestiture plan	(851)		5		(846)
Other restructuring programs (2)	(612)		47		(565)
Restructuring charges	$	77	$	154	$	231

Three Months Ended September 25, 2022
	Termination Benefits		Other Costs (1)		Total
Respiratory divestiture plan	$	123	$	22	$	145
2019 Footprint realignment plan	(50)		16		(34)
2018 Footprint realignment plan	203		252		455
Other restructuring programs (3)	24		38		62
Restructuring charges	$	300	$	328	$	628

Nine Months Ended October 1, 2023
	Termination Benefits		Other Costs (1)		Total
2023 Footprint realignment plan	$	1,296	$	—	$	1,296
2022 Restructuring plan	3,361		313		3,674
Respiratory divestiture plan	(596)		17		(579)
Other restructuring programs (2)	(853)		422		(431)
Restructuring charges	$	3,208	$	752	$	3,960

Nine Months Ended September 25, 2022
	Termination Benefits		Other Costs (1)		Total
Respiratory divestiture plan	$	358	$	67	$	425
2019 Footprint realignment plan	(1,120)		61		(1,059)
2018 Footprint realignment plan	514		547		1,061
Other restructuring programs (3)	750		276		1,026
Restructuring charges	502		951		1,453
Asset impairment charges	—		1,497		1,497
Restructuring and impairment charges	$	502	$	2,448	$	2,950

(1) Other costs include facility closure, contract termination and other exit costs.

(2) Includes activity primarily related to a restructuring plan initiated in the first quarter of 2022 that is designed to relocate manufacturing operations at certain of our facilities (the "2022 Manufacturing relocation plan") and our 2014, 2018, and 2019 Footprint realignment plans.

(3) Includes activity primarily related to the 2022 Manufacturing relocation plan, the 2021 Restructuring plan and the 2014 Footprint realignment plan.

9

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

2023 Footprint Realignment plan

In September 2023, we initiated a restructuring plan primarily involving the relocation of certain manufacturing operations to existing lower-cost locations, the outsourcing of certain manufacturing processes and related workforce reductions (the "2023 Footprint realignment plan"). These actions are expected to be substantially completed by the end of 2027. The following table provides a summary of our estimates of restructuring and restructuring related charges by major type of expense associated with the 2023 Footprint realignment plan:

	Total estimated amount expected to be incurred
Plan expense estimates:	(Dollars in millions)
Restructuring charges (1)	$4 million to $6 million
Restructuring related charges (2)	$7 million to $9 million
Total restructuring and restructuring related charges	$11 million to $15 million

(1) Substantially all of the charges consist of employee termination benefit costs.

(2)Restructuring related charges represent costs that are directly related to the 2023 Footprint realignment plan and principally constitute costs to transfer manufacturing operations to existing lower-cost locations and project management costs. Substantially all of these charges are expected to be recognized within cost of goods sold.

We expect substantially all of the restructuring and restructuring related charges will result in future cash outlays, the majority of which will be made between 2024 and 2025. Additionally, we expect to incur $2 million to $3 million in aggregate capital expenditures under the plan, which are expected to be incurred mostly in 2024.

As of October 1, 2023, we maintain a restructuring reserve of $1.3 million in connection with this plan, all of which relate to termination benefits.

Respiratory divestiture plan

During 2021, in connection with the Respiratory business divestiture, we committed to a restructuring plan designed to separate the manufacturing operations to be transferred to Medline from those that will remain with Teleflex, which includes related workforce reductions (the “Respiratory divestiture plan”). The plan includes expanding certain of our existing locations to accommodate the transfer of capacity from the sites being transferred to Medline and replicating the manufacturing processes at alternate existing locations. We expect this plan will be substantially completed by the end of 2023. The following table provides a summary of our cost estimates by major type of expense associated with the Respiratory divestiture plan:

	Total estimated amount expected to be incurred
Plan expense estimates:	(Dollars in millions)
Restructuring charges (1)	$3 million to $3 million
Restructuring related charges (2)	$19 million to $21 million
Total restructuring and restructuring related charges	$22 million to $24 million

(1) Substantially all of the charges consist of employee termination benefit costs.

(2)Consist of charges that are directly related to the Respiratory divestiture plan and principally constitute costs to transfer manufacturing operations to other locations and project management costs. Substantially all of the charges are expected to be recognized within costs of goods sold.

We expect substantially all of the restructuring and restructuring related charges will result in future cash outlays, and we expect to incur $22 million to $24 million in aggregate capital expenditures under the plan.

We recorded restructuring related charges with respect to the Respiratory divestiture plan of $1.6 million and $5.6 million for the three and nine months ended October 1, 2023, respectively, and $2.1 million and $6.5 million for the three and nine months ended September 25, 2022, respectively. The restructuring related charges were included within cost of goods sold.

10

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

As of October 1, 2023, we have incurred net aggregate restructuring expenses related to the Respiratory divestiture plan of $2.7 million. Additionally, as of October 1, 2023, we have incurred net aggregate restructuring related charges in connection with the Respiratory divestiture plan of $17.9 million, which were primarily included in cost of goods sold. As of October 1, 2023, we have a restructuring reserve of $2.5 million in connection with this plan.

2022 Restructuring plan

In November 2022, we initiated a strategic restructuring plan designed to improve operating performance and position the organization to deliver long-term durable growth by creating efficiencies that align with our high growth strategic objectives (the “2022 Restructuring plan”). The plan is substantially complete and as a result, we expect future restructuring expenses associated with the plan, if any, to be immaterial.

Note 6 — Inventories

Inventories as of October 1, 2023 and December 31, 2022 consisted of the following:

	October 1, 2023		December 31, 2022
Raw materials	$	186,216	$	186,641
Work-in-process	111,371		98,993
Finished goods	327,488		292,873
Inventories	$	625,075	$	578,507

Note 7 — Goodwill and other intangible assets

The following table provides information relating to changes in the carrying amount of goodwill by reportable operating segment for the nine months ended October 1, 2023:

	Americas		EMEA		Asia		OEM		Total
December 31, 2022	$	1,731,093	$	468,524	$	225,103	$	112,010	$	2,536,730
Currency translation adjustment	2,608		(4,011)		(7,022)		—		(8,425)
October 1, 2023	$	1,733,701	$	464,513	$	218,081	$	112,010	$	2,528,305

The gross carrying amount of, and accumulated amortization relating to, intangible assets as of October 1, 2023 and December 31, 2022 were as follows:

	Gross Carrying Amount				Accumulated Amortization
	October 1, 2023		December 31, 2022		October 1, 2023		December 31, 2022
Customer relationships	$	1,326,706	$	1,328,539	$	(542,216)	$	(497,335)
In-process research and development	26,979		27,075		—		—
Intellectual property	1,600,259		1,599,355		(714,308)		(646,643)
Distribution rights	23,087		23,115		(21,643)		(21,090)
Trade names	562,461		564,023		(80,787)		(71,128)
Non-compete agreements	21,311		21,429		(21,310)		(21,175)
	$	3,560,803	$	3,563,536	$	(1,380,264)	$	(1,257,371)

11

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

Note 8 — Borrowings

Our borrowings at October 1, 2023 and December 31, 2022 were as follows:

	October 1, 2023		December 31, 2022
Senior Credit Facility:
Revolving credit facility, at a rate of 6.67% at October 1, 2023, due 2027	$	482,000	$	148,250
Term loan facility, at a rate of 6.67% at October 1, 2023, due 2027	490,625		500,000
4.625% Senior Notes due 2027	500,000		500,000
4.25% Senior Notes due 2028	500,000		500,000
Securitization program, at a rate of 6.29% at October 1, 2023	75,000		75,000
	2,047,625		1,723,250
Less: Unamortized debt issuance costs	(10,002)		(11,727)
	2,037,623		1,711,523
Current borrowings	(87,500)		(87,500)
Long-term borrowings	$	1,950,123	$	1,624,023

Note 9 — Financial instruments

Foreign currency forward contracts

We use derivative instruments for risk management purposes. Foreign currency forward contracts designated as cash flow hedges are used to manage foreign currency transaction exposure. Foreign currency forward contracts not designated as hedges for accounting purposes are used to manage exposure related to near term foreign currency denominated monetary assets and liabilities. We enter into the non-designated foreign currency forward contracts for periods consistent with our currency translation exposures, which generally approximate one month. For the three and nine months ended October 1, 2023, we recognized a loss of $1.0 million and a gain of $1.0 million, respectively, related to non-designated foreign currency forward contracts. For the three and nine months ended September 25, 2022, we recognized losses of $1.0 million and $4.2 million, respectively, related to non-designated foreign currency forward contracts.

The total notional amount for all open foreign currency forward contracts designated as cash flow hedges as of October 1, 2023 and December 31, 2022 was $238.1 million and $184.8 million, respectively. The total notional amount for all open non-designated foreign currency forward contracts as of October 1, 2023 and December 31, 2022 was $140.3 million and $152.9 million, respectively. All open foreign currency forward contracts as of October 1, 2023 have durations of 12 months or less.

Cross-currency interest rate swaps

During 2019, we entered into cross-currency swap agreements with five different financial institution counterparties to hedge against the effect of variability in the U.S. dollar to euro exchange rate. Under the terms of the cross-currency swap agreements, we have notionally exchanged $250 million at an annual interest rate of 4.88% for €219.2 million at an annual interest rate of 2.46%. The swap agreements are designed as net investment hedges and expire on March 4, 2024.

During 2018, we entered into cross-currency swap agreements with six different financial institution counterparties to hedge against the effect of variability in the U.S. dollar to euro exchange rate (the "2018 Cross-currency swap"). Under the terms of the cross-currency swap agreements, we have notionally exchanged $500 million at an annual interest rate of 4.63% for €433.9 million at an annual interest rate of 1.94%. The swap agreements are designed as net investment hedges. For further discussion related to the 2018 Cross-currency swap refer to subsequent event section below.

The swap agreements described above require an exchange of the notional amounts upon expiration or earlier termination of the agreements. We and the counterparties have agreed to effect the exchange through a net settlement.

12

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

The cross-currency swaps are marked to market at each reporting date and any changes in fair value are recognized as a component of accumulated other comprehensive income (loss) ("AOCI"). The following table summarizes the foreign exchange gains and losses recognized within AOCI and the interest benefit recognized within interest expense related to cross currency swap for the three and nine months ended October 1, 2023 and September 25, 2022:

	Three Months Ended				Nine Months Ended
	October 1, 2023		September 25, 2022		October 1, 2023		September 25, 2022
Foreign exchange gain	$	15,756	$	42,189	$	1,466	$	68,643
Interest benefit	5,171		5,531		15,459		15,677

Subsequent event

On October 4, 2023, the third day of our fourth quarter, the agreements related to our 2018 Cross-currency swap matured resulting in $43.0 million in cash settlement proceeds. On October 2, 2023, we executed new cross-currency swap agreements with six different financial institution counterparties to hedge against the effect of variability in the U.S. dollar to euro exchange rate. Under the terms of the cross-currency swap agreements, we have notionally exchanged $500 million at an annual interest rate of 4.63% for €474.7 million at an annual interest rate of 3.05%. The swap agreements are designated as net investment hedges and expire on October 4, 2025.

Balance sheet presentation

The following table presents the locations in the condensed consolidated balance sheet and fair value of derivative financial instruments as of October 1, 2023 and December 31, 2022:

	October 1, 2023		December 31, 2022
	Fair Value
Asset derivatives:
Designated foreign currency forward contracts	$	4,288	$	3,154
Non-designated foreign currency forward contracts	158		41
Cross-currency interest rate swaps	67,500		48,503
Prepaid expenses and other current assets	71,946		51,698
Cross-currency interest rate swaps	—		11,912
Other assets	—		11,912
Total asset derivatives	$	71,946	$	63,610
Liability derivatives:
Designated foreign currency forward contracts	$	2,819	$	983
Non-designated foreign currency forward contracts	422		477
Other current liabilities	3,241		1,460
Total liability derivatives	$	3,241	$	1,460

See Note 11 for information on the location and amount of gains and losses attributable to derivatives that were reclassified from AOCI to expense (income), net of tax. There was no ineffectiveness related to our cash flow hedges during the three and nine months ended October 1, 2023 and September 25, 2022.

Trade receivables

The allowance for credit losses as of October 1, 2023 and December 31, 2022 was $9.1 million and $8.6 million, respectively. The current portion of the allowance for credit losses, which was $5.2 million and $4.9 million as of October 1, 2023 and December 31, 2022, respectively, was recognized as a reduction of accounts receivable, net.

13

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

Note 10 — Fair value measurement

The following tables provide information regarding our financial assets and liabilities measured at fair value on a recurring basis as of October 1, 2023 and December 31, 2022:

	Total carrying  value at  October 1, 2023		Quoted prices in active markets (Level 1)		Significant other observable Inputs (Level 2)		Significant unobservable Inputs (Level 3)
Investments in marketable securities	$	4,761	$	4,761	$	—	$	—
Derivative assets	71,946		—		71,946		—
Derivative liabilities	3,241		—		3,241		—
Contingent consideration liabilities	18,302		—		—		18,302

	Total carrying value at December 31, 2022		Quoted prices in active markets (Level 1)		Significant other observable Inputs (Level 2)		Significant unobservable Inputs (Level 3)
Investments in marketable securities	$	10,097	$	10,097	$	—	$	—
Derivative assets	63,610		—		63,610		—
Derivative liabilities	1,460		—		1,460		—
Contingent consideration liabilities	44,022		—		—		44,022

Valuation Techniques

Our financial assets valued based upon Level 1 inputs are comprised of investments in marketable securities held in trust, which are available to satisfy benefit obligations under our benefit plans and other arrangements. The investment assets of the trust are valued using quoted market prices.

Our financial assets and liabilities valued based upon Level 2 inputs are comprised of foreign currency forward contracts and cross-currency interest rate swap agreements. We use foreign currency forwards and cross-currency interest rate swaps to manage foreign currency transaction exposure, as well as exposure to foreign currency denominated monetary assets and liabilities. We measure the fair value of the foreign currency forwards and cross-currency swaps by calculating the amount required to enter into offsetting contracts with similar remaining maturities, based on quoted market prices, and taking into account the creditworthiness of the counterparties.

Our financial liabilities valued based upon Level 3 inputs (inputs that are not observable in the market) are comprised of contingent consideration arrangements pertaining to our acquisitions.

Contingent consideration

Contingent consideration liabilities, which primarily consist of payment obligations that are contingent upon the achievement of revenue-based goals, but also can be based on other milestones such as regulatory approvals, are remeasured to fair value each reporting period using assumptions including estimated revenues (based on internal operational budgets and long-range strategic plans), discount rates, probability of payment and projected payment dates.

We determine the fair value of certain contingent consideration liabilities using a Monte Carlo simulation (which involves a simulation of future revenues during the earn-out period using management's best estimates) or discounted cash flow analysis. Increases in projected revenues, estimated cash flows and probabilities of payment may result in significantly higher fair value measurements; decreases in these items may have the opposite effect. Increases in the discount rates in periods prior to payment may result in significantly lower fair value measurements and decreases in the discount rates may have the opposite effect.

14

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

The table below provides additional information regarding the valuation technique and inputs used in determining the fair value of our significant contingent consideration liabilities.

Contingent Consideration Liability	Valuation Technique	Unobservable Input
Revenue-based
	Monte Carlo simulation	Revenue volatility	30.6	%
		Risk free rate	Cost of debt structure
		Projected year of payment	2024 - 2026

The following table provides information regarding changes in our contingent consideration liabilities for the three and nine months ended October 1, 2023:

	Contingent consideration
Balance – December 31, 2022	$	44,022
Payments	(1,238)
Revaluations	(24,482)
Balance – October 1, 2023	$	18,302

Note 11 — Shareholders' equity

Basic earnings per share is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted earnings per share is computed in the same manner except that the weighted average number of shares is increased to include dilutive securities. The following table provides a reconciliation of basic to diluted weighted average number of common shares outstanding:

	Three Months Ended		Nine Months Ended
	October 1, 2023	September 25, 2022	October 1, 2023	September 25, 2022
Basic	46,992	46,906	46,974	46,894
Dilutive effect of share-based awards	307	357	330	443
Diluted	47,299	47,263	47,304	47,337

The weighted average number of shares that were antidilutive and therefore excluded from the calculation of earnings per share were 0.8 million and 0.7 million for the three and nine months ended October 1, 2023, respectively, and 0.7 million and 0.5 million for the three and nine months ended September 25, 2022, respectively.

The following tables provide information relating to the changes in accumulated other comprehensive loss, net of tax, for the nine months ended October 1, 2023 and September 25, 2022:

	Cash Flow Hedges		Pension and Other Postretirement Benefit Plans		Foreign Currency Translation Adjustment		Accumulated Other Comprehensive (Loss) Income
Balance as of December 31, 2022	$	4,931	$	(135,799)	$	(272,654)	$	(403,522)
Other comprehensive income (loss) before reclassifications	9,109		(76)		(13,368)		(4,335)
Amounts reclassified from accumulated other comprehensive (loss) income	(8,320)		4,027		—		(4,293)
Net current-period other comprehensive income (loss)	789		3,951		(13,368)		(8,628)
Balance as of October 1, 2023	$	5,720	$	(131,848)	$	(286,022)	$	(412,150)

15

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

	Cash Flow Hedges		Pension and Other Postretirement Benefit Plans		Foreign Currency Translation Adjustment		Accumulated Other Comprehensive (Loss) Income
Balance as of December 31, 2021	$	1,081	$	(138,290)	$	(209,750)	$	(346,959)
Other comprehensive income (loss) before reclassifications	6,871		1,980		(123,576)		(114,725)
Amounts reclassified from accumulated other comprehensive (loss) income	(1,335)		3,827		—		2,492
Net current-period other comprehensive income (loss)	5,536		5,807		(123,576)		(112,233)
Balance as of September 25, 2022	$	6,617	$	(132,483)	$	(333,326)	$	(459,192)

The following table provides information relating to the location in the statements of operations and amount of reclassifications of losses/(gains) in accumulated other comprehensive (loss) income into (income) expense, net of tax, for the three and nine months ended October 1, 2023 and September 25, 2022:

	Three Months Ended				Nine Months Ended
	October 1, 2023		September 25, 2022		October 1, 2023		September 25, 2022
(Gains) Loss on foreign exchange contracts:
Cost of goods sold	$	(3,499)	$	(1,614)	$	(8,734)	$	(1,445)
Total before tax	(3,499)		(1,614)		(8,734)		(1,445)
Taxes	34		84		414		110
Net of tax	(3,465)		(1,530)		(8,320)		(1,335)
Amortization of pension and other postretirement benefit items (1):
Actuarial losses	1,851		1,758		5,986		5,747
Prior-service costs	(252)		(252)		(756)		(756)
Total before tax	1,599		1,506		5,230		4,991
Tax benefit	(368)		(352)		(1,203)		(1,164)
Net of tax	1,231		1,154		4,027		3,827
Total reclassifications, net of tax	$	(2,234)	$	(376)	$	(4,293)	$	2,492

(1) These accumulated other comprehensive (loss) income components are included in the computation of net benefit expense for pension and other postretirement benefit plans.

Note 12 — Taxes on income from continuing operations

	Three Months Ended		Nine Months Ended
	October 1, 2023	September 25, 2022	October 1, 2023	September 25, 2022
Effective income tax rate	8.0%	14.5%	12.7%	15.4%

The effective income tax rates for the three and nine months ended October 1, 2023 were 8.0% and 12.7%, respectively. The effective income tax rates for the three and nine months ended October 1, 2023 reflect the tax impact of a non-taxable contingent consideration adjustment recognized in connection with a decrease in the estimated fair value of our contingent consideration liabilities and tax benefits related to the 2023 Footprint Realignment plan and the 2022 Restructuring plan. The effective income tax rates for all periods reflect a tax benefit from research and development credits.

Note 13 — Commitments and contingent liabilities

Environmental: We are subject to contingencies as a result of environmental laws and regulations that in the future may require us to take further action to correct the effects on the environment of prior disposal practices or releases of chemical or petroleum substances by us or other parties. Much of this liability results from the U.S. Comprehensive Environmental Response, Compensation and Liability Act, often referred to as Superfund, the U.S. Resource Conservation and Recovery Act and similar state laws. These laws require us to undertake certain

16

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

investigative and remedial activities at sites where we conduct or once conducted operations or at sites where Company-generated waste was disposed.

Remediation activities vary substantially in duration and cost from site to site. These activities, and their associated costs, depend on the mix of unique site characteristics, evolving remediation technologies, the regulatory agencies involved and their enforcement policies, as well as the presence or absence of other potentially responsible parties. At October 1, 2023, we have recorded $2.5 million and $4.1 million in accrued liabilities and other liabilities, respectively, relating to these matters. Considerable uncertainty exists with respect to these liabilities and, if adverse changes in circumstances occur, the potential liability may exceed the amount accrued as of October 1, 2023. The time frame over which the accrued amounts may be paid out, based on past history, is estimated to be 10-15 years.

Legal matters: We are a party to various lawsuits and claims arising in the normal course of business. These lawsuits and claims include actions involving product liability, product warranty, commercial disputes, intellectual property, contract, employment, environmental and other matters. As of October 1, 2023, we have recorded accrued liabilities of $0.6 million in connection with such contingencies, representing our best estimate of the cost within the range of estimated possible losses that will be incurred to resolve these matters.

Based on information currently available, advice of counsel, established reserves and other resources, we do not believe that the outcome of any outstanding litigation and claims is likely to be, individually or in the aggregate, material to our business, financial condition, results of operations or liquidity. However, in the event of unexpected further developments, it is possible that the ultimate resolution of these matters, or other similar matters, if unfavorable, may be materially adverse to our business, financial condition, results of operations or liquidity. Legal costs such as outside counsel fees and expenses are charged to selling, general and administrative expenses in the period incurred.

Other: In 2015, the Italian parliament enacted legislation that, among other things, imposed a “payback” measure on medical device companies that supply goods and services to the Italian National Healthcare System. Under the measure, companies are required to make payments to the Italian government if medical device expenditures in a given year exceed regional expenditure ceilings established for that year. The payment amounts are calculated based on the amount by which the regional ceilings for the given year were exceeded. Considerable uncertainty exists related to the enforceability of and implementation process for the payback law. In response to decrees issued by the Italian Ministry of Health, the various Italian regions issued invoices to medical device companies, including Teleflex, under the payback measure in the fourth quarter of 2022 seeking payment with respect to excess expenditures for the years 2015 through 2018. Following the issuance of the invoices, we and numerous other medical device companies filed appeals with the Italian administrative courts challenging the enforceability of the payback measure, which appeals remain pending. As of October 1, 2023, our reserve for this matter was $12.9 million, of which $2.2 million was recorded as a reduction of revenue in 2023. If the payback was to ultimately be enforced in its existing form, we estimate that we would be required to remit payments in excess of our current reserve of up to $18.6 million.

On April 4, 2023, one of our Mexican subsidiaries received a notification from the Mexican Federal Tax Administration Service (“SAT”) setting forth its preliminary findings with respect to a foreign trade operations audit carried out by SAT for the period from July 1, 2017 to June 6, 2019. The preliminary findings stated that our Mexican subsidiary did not evidence the export of goods temporarily imported under Mexico’s Manufacturing, Maquila and Export Services Industries Program (“IMMEX Program”), therefore triggering the potential obligation for payment of import duties, value added tax, customs processing fees and other fines and penalties. In response to the notification, our Mexican subsidiary has requested that the matter be referred to the Procuraduría de la Defensa del Contribuyente, or “PRODECON,” (local tax ombudsperson) to help facilitate the process. In June, SAT was provided with the appropriate documentation evidencing the export of the goods in accordance with the requirements of the IMMEX Program.

While we cannot predict with certainty the outcome of this audit, based on currently known information, we do not believe a loss is either probable or estimable. Accordingly, no loss contingency has been recorded in our financial statements as of October 1, 2023 related to this matter. However, if the final resolution of the matter is not favorable to us, our Mexican subsidiary may be required to make payment of certain import duties, fines and surcharges, which could be material.

17

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

Tax audits and examinations: We are routinely subject to tax examinations by various tax authorities. As of October 1, 2023, the most significant tax examinations in process were in Ireland and Germany. We may establish reserves with respect to our uncertain tax positions, after we adjust the reserves to address developments with respect to our uncertain tax positions, including developments in these tax examinations. Accordingly, developments in tax audits and examinations, including resolution of uncertain tax positions, could result in increases or decreases to our recorded tax liabilities, which could impact our financial results.

Note 14 — Segment information

The following tables present our segment results for the three and nine months ended October 1, 2023 and September 25, 2022:

	Three Months Ended				Nine Months Ended
	October 1, 2023		September 25, 2022		October 1, 2023		September 25, 2022
Americas	$	428,206	$	405,038	$	1,264,714	$	1,195,739
EMEA	142,723		128,437		433,872		410,535
Asia	93,151		82,025		258,560		227,824
OEM	82,309		71,288		243,434		198,947
Net revenues	$	746,389	$	686,788	$	2,200,580	$	2,033,045

	Three Months Ended				Nine Months Ended
	October 1, 2023		September 25, 2022		October 1, 2023		September 25, 2022
Americas	$	126,340	$	107,180	$	341,261	$	318,548
EMEA	17,876		7,472		43,744		29,291
Asia	25,978		22,885		70,126		61,796
OEM	23,491		18,438		67,307		47,197
Total segment operating profit (1)	193,685		155,975		522,438		456,832
Unallocated expenses (2)	(28,375)		(23,530)		(98,593)		(85,694)
Income from continuing operations before interest and taxes	$	165,310	$	132,445	$	423,845	$	371,138

(1)Segment operating profit includes segment net revenues from external customers reduced by its standard cost of goods sold, adjusted for fixed manufacturing cost absorption variances, selling, general and administrative expenses, research and development expenses and an allocation of corporate expenses.

(2)Unallocated expenses primarily include manufacturing variances other than fixed manufacturing cost absorption variances and restructuring and impairment charges.

18

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Overview

Teleflex Incorporated (“we,” “us,” “our" and “Teleflex”) is a global provider of medical technology products focused on enhancing clinical benefits, improving patient and provider safety and reducing total procedural costs. We primarily design, develop, manufacture and supply single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. We market and sell our products worldwide through a combination of our direct sales force and distributors. Because our products are used in numerous markets and for a variety of procedures, we are not dependent upon any one end-market or procedure. We are focused on achieving consistent, sustainable and profitable growth by increasing our market share and improving our operating efficiencies.

We evaluate our portfolio of products and businesses on an ongoing basis to ensure alignment with our overall objectives. Based on our evaluation, we may identify opportunities to divest businesses and product lines that do not meet our objectives. In addition, we may seek to optimize utilization of our facilities through restructuring initiatives designed to further improve our cost structure and enhance our competitive position. We also may continue to explore opportunities to expand the size of our business and improve operating margins through a combination of acquisitions and distributor to direct sales conversions, which generally involve our elimination of a distributor from the sales channel, either by acquiring the distributor or terminating the distributor relationship (in some instances, particularly in Asia, the conversions involve our acquisition or termination of a master distributor and the continued sale of our products through sub-distributors or through new distributors). Distributor to direct sales conversions are designed to facilitate improved product pricing and more direct access to the end users of our products within the sales channel.

In May 2023, our Board of Directors approved the termination of the Teleflex Incorporated Retirement Income Plan (the “TRIP”), a U.S. defined benefit plan, effective as of August 1, 2023. The TRIP is subject to the Employee Retirement Income Security Act of 1974, as amended (“ERISA”), and is intended to be tax-qualified under Section 401(a) of the Internal Revenue Code of 1986, as amended (“Code”). Participation in and accrual of benefits under the TRIP have been frozen since 2012, and, as of October 1, 2023, the TRIP assets exceeded the liabilities. In June 2023, we notified participants of our intent to terminate the TRIP and requested a determination letter from the Internal Revenue Services (“IRS”) stating that the TRIP satisfies the requirements, in form, to be tax-qualified under Code Section 401(a) upon termination. In September 2023, a notice of benefits was sent to participants, beneficiaries and alternate payees in connection with the proposed termination. Participants, beneficiaries and alternate payees who had not started their TRIP benefits were offered the opportunity to elect to receive their benefits in the form of a lump sum distribution in connection with the termination of the TRIP or to commence their benefits in the form of monthly annuity payments in accordance with TRIP terms. Because the TRIP is an ERISA plan, the termination is subject to approval by the Pension Benefit Guaranty Corporation (“PBGC”). In September 2023, we filed a termination notice with the PBGC for approval. After the termination has been approved by the PBGC, one or more annuity contracts with a qualifying insurer(s) will be purchased to provide TRIP benefits that have not already been distributed. While we expect to proceed with the termination, we may decide not to proceed for certain reasons including, for example, if the cost to terminate the TRIP exceeds our current expectations. Should the Company proceed with the termination, participants, beneficiaries, and alternate payees will each receive the full value of their benefit under the TRIP, paid either from TRIP assets or from an annuity contract purchase as described under this paragraph.

Upon settlement of the TRIP, we are required to remeasure the plan assets and obligation and will recognize a settlement loss for the recognition of the unrecognized losses in accumulated other comprehensive income including the effects of the remeasurement. As of October 1, 2023, the pre-tax accumulated other comprehensive loss related to the TRIP was approximately $200 million. We expect to recognize a portion of the settlement charge during the fourth quarter of 2023, when eligible participants who elect the lump sum option receive their payments, and we expect to recognize the remainder of the settlement charge upon annuitization of the TRIP benefits, which we expect to occur during 2024. Based on notices we have processed from participants electing the lump sum option to receive their payments, we estimate we will recognize a settlement charge of between $45 million and $55 million during the fourth quarter of 2023.

On July 25, 2023, we executed a definitive agreement to acquire Palette Life Sciences AB (“Palette”), a privately held medical device company that sells a portfolio of hyaluronic acid gel-based products primarily utilized in the treatment of urology diseases including a rectal spacing product used in connection with radiation therapy treatment of prostate cancer. The acquisition will complement our interventional urology product portfolio. On October 10,

19

2023, we completed the acquisition of Palette using borrowings under our revolving credit facility and cash on hand. Under the terms of the agreement, we acquired Palette for an initial cash payment of $600 million, with additional consideration of up to $50 million payable upon the achievement of certain commercial milestones.

Results of Operations

As used in this discussion, "new products" are products for which commercial sales have commenced within the past 36 months, and “existing products” are products for which commercial sales commenced more than 36 months ago. Discussion of results of operations items that reference the effect of one or more acquired and/or divested businesses or assets (except as noted below with respect to acquired distributors) generally reflects the impact of the acquisitions and/or divestitures within the first 12 months following the date of the acquisition and/or divestiture. In addition to increases and decreases in the per unit selling prices of our products to our customers, our discussion of the impact of product price increases and decreases also reflects the impact on the pricing of our products resulting from the elimination of the distributor, either through acquisition or termination of the distributor, from the sales channel. All of the dollar amounts in the tables are presented in millions unless otherwise noted.

Certain financial information is presented on a rounded basis, which may cause minor differences.

Net revenues

	Three Months Ended				Nine Months Ended
	October 1, 2023		September 25, 2022		October 1, 2023		September 25, 2022
Net revenues	$	746.4	$	686.8	$	2,200.6	$	2,033.0

Net revenues for the three months ended October 1, 2023 increased $59.6 million, or 8.7%, compared to the prior year period, primarily due to a $29.9 million increase in sales of new products, price increases and, to a lesser extent, favorable fluctuations in foreign currency exchange rates.

Net revenues for the nine months ended October 1, 2023 increased $167.6 million, or 8.2%, compared to the prior year period, primarily due to a $142.0 million increase in sales of new products and price increases, partially offset by a $31.4 million decrease in sales volume of existing products, notwithstanding the impact of a five-day increase in the number of shipping days during the nine months ended October 1, 2023. The increase in sales of new products and the decrease in sales of volumes of existing products primarily reflect the conversion to the next generation of an existing product.

Gross profit

	Three Months Ended						Nine Months Ended
	October 1, 2023			September 25, 2022			October 1, 2023			September 25, 2022
Gross profit	$	416.3		$	374.0		$	1,215.5		$	1,109.0
Percentage of sales	55.8		%	54.4		%	55.2		%	54.5		%

Gross margin for the three months ended October 1, 2023 increased 140 basis points, or 2.6%, compared to the prior year period, primarily due to price increases, benefits from cost improvement initiatives and lower logistics and distribution related costs, partially offset by continued cost inflation from macro-economic factors, specifically, raw materials and unfavorable fluctuations in foreign currency exchange rates.

Gross margin for the nine months ended October 1, 2023 increased 70 basis points, or 1.3%, compared to the prior year period, primarily due to price increases, lower logistics and distribution related costs and benefits from cost improvement initiatives, partially offset by continued cost inflation from macro-economic factors, specifically, raw materials, an unfavorable impact on manufacturing productivity due to raw material supply and an increase in costs associated with product recalls and quality issues.

On April 4, 2023, one of our Mexican subsidiaries received a notification from the Mexican Federal Tax Administration Service (“SAT”) setting forth its preliminary findings with respect to a foreign trade operations audit carried out by SAT for the period from July 1, 2017 to June 6, 2019. The preliminary findings stated that our Mexican subsidiary did not evidence the export of goods temporarily imported under Mexico’s Manufacturing, Maquila and Export Services Industries Program (“IMMEX Program”), therefore triggering the potential obligation for payment of import duties, value added tax, customs processing fees and other fines and penalties. In response to the notification, our Mexican subsidiary has requested that the matter be referred to the Procuraduría de la Defensa del Contribuyente, or “PRODECON,” (local tax ombudsperson) to help facilitate the process. In June, SAT was provided with the appropriate documentation evidencing the export of the goods in accordance with the requirements of the IMMEX Program.

20

While we cannot predict with certainty the outcome of this audit, based on currently known information, we do not believe a loss is either probable or estimable. Accordingly, no loss contingency has been recorded in our financial statements as of October 1, 2023 related to this matter. However, if the final resolution of the matter is not favorable to us, our Mexican subsidiary may be required to make payment of certain import duties, fines and surcharges, which could be material.

Selling, general and administrative

	Three Months Ended						Nine Months Ended
	October 1, 2023			September 25, 2022			October 1, 2023			September 25, 2022
Selling, general and administrative	$	213.2		$	209.6		$	669.2		$	630.4
Percentage of sales	28.6		%	30.5		%	30.4		%	31.0		%

Selling, general and administrative expenses for the three months ended October 1, 2023 increased $3.6 million, compared to the prior year period primarily due to higher sales expenses across certain of our product portfolios, higher performance related employee-benefit costs, higher expenses incurred by acquired businesses, primarily Standard Bariatrics, unfavorable fluctuations in foreign currency exchange rates and, to a lesser extent, higher IT related costs. The increases in selling, general and administrative expenses were partially offset by a decrease in contingent consideration expense resulting from changes in the estimated fair value of our contingent consideration liabilities.

Selling, general and administrative expenses for the nine months ended October 1, 2023 increased $38.8 million, compared to the prior year period primarily due to higher sales expenses across certain of our product portfolios, higher operating expenses incurred by acquired businesses, primarily Standard Bariatrics, higher IT related costs and higher performance related employee-benefit costs. The increases in selling, general and administrative expenses were partially offset by a decrease in contingent consideration expense resulting from changes in the estimated fair value of our contingent consideration liabilities.

Research and development

	Three Months Ended						Nine Months Ended
	October 1, 2023			September 25, 2022			October 1, 2023			September 25, 2022
Research and development	$	37.6		$	37.8		$	118.5		$	111.1
Percentage of sales	5.0		%	5.5		%	5.4		%	5.5		%

The decrease in research and development expenses for the three months ended October 1, 2023 compared to the prior year period was primarily attributable to lower expenses related to the European Union Medical Device Regulation related costs, partially offset by higher project spend within certain of our product portfolios and expenses incurred by Standard Bariatrics.

The increase in research and development expenses for the nine months ended October 1, 2023 compared to the prior year period was primarily attributable to higher project spend within certain of our product portfolios and expenses incurred by Standard Bariatrics, partially offset by lower expenses related to the European Union Medical Device Regulation related costs.

Restructuring and impairment charges

	Three Months Ended				Nine Months Ended
	October 1, 2023		September 25, 2022		October 1, 2023		September 25, 2022
Restructuring and impairment charges	$	0.2	$	0.6	$	4.0	$	3.0

Restructuring charges for the three months ended October 1, 2023 primarily consisted of termination benefits related to the 2023 Footprint realignment plan, partially offset by credits due to changes in estimates with respect to termination benefits related to the Respiratory divestiture plan.

Restructuring charges for the nine months ended October 1, 2023 primarily consisted of termination benefits related to the 2023 Footprint realignment plan and the 2022 Restructuring plan, partially offset by credits due to changes in estimates with respect to termination benefits related to the Respiratory divestiture plan.

2023 Footprint Realignment plan

During the third quarter of 2023, we initiated a restructuring plan primarily involving the relocation of certain

21

manufacturing operations to existing lower-cost locations, the outsourcing of certain manufacturing processes and related workforce reductions (the "2023 Footprint realignment plan"). We estimate that we will incur $11 million to $15 million in aggregate pre-tax restructuring and restructuring related charges in connection with the 2023 Footprint Realignment plan. We expect this plan will be substantially completed by the end of 2027.

We expect to begin realizing plan-related savings in 2024 and expect to achieve annual pre-tax savings of $2 million to $4 million once the plan is fully implemented.

Respiratory divestiture plan

We have an ongoing restructuring initiative, initiated in connection with the Respiratory business divestiture, designed to separate the manufacturing operations to be transferred to Medline from those that will remain with Teleflex (the “Respiratory divestiture plan”). We estimate that we will incur aggregate pre-tax restructuring and restructuring related charges in connection with the Respiratory divestiture plan of $22 million to $24 million. We expect this plan will be substantially completed by the end of 2023.

For additional information regarding our restructuring plans, refer to Note 5 within the condensed consolidated financial statements included in this report.

Interest income and expense

	Three Months Ended						Nine Months Ended
	October 1, 2023			September 25, 2022			October 1, 2023			September 25, 2022
Interest expense	$	23.2		$	13.4		$	59.3		$	35.2
Average interest rate on debt	4.6		%	3.0		%	4.3		%	2.5		%
Interest income	$	(7.5)		$	(0.1)		$	(9.5)		$	(0.6)

The increase in interest expense for the three months ended October 1, 2023 compared to the prior year period was primarily due to higher average interest rates resulting from increases in interest rates associated with our variable interest rate debt instruments and an increase in average debt outstanding.

The increase in interest expense for the nine months ended October 1, 2023 compared to the prior year period was primarily due to higher average interest rates resulting from increases in interest rates associated with our variable interest rate debt instruments.

Interest income for the three and nine months ended October 1, 2023 increased compared to the prior year periods primarily due to higher investments in time deposits and money market mutual funds.

Taxes on income from continuing operations

	Three Months Ended				Nine Months Ended
	October 1, 2023		September 25, 2022		October 1, 2023		September 25, 2022
Effective income tax rate	8.0	%	14.5	%	12.7	%	15.4	%

The effective income tax rates for the three and nine months ended October 1, 2023 reflect the tax impact of a non-taxable contingent consideration adjustment recognized in connection with a decrease in the estimated fair value of our contingent consideration liabilities and tax benefits related to the 2023 Footprint Realignment plan and the 2022 Restructuring plan. The effective income tax rates for all periods reflect a tax benefit from research and development credits.

Segment net revenues
	Three Months Ended					Nine Months Ended
	October 1, 2023		September 25, 2022		% Increase/(Decrease)	October 1, 2023		September 25, 2022		% Increase/ (Decrease)
Americas	$	428.2	$	405.1	5.7	$	1,264.7	$	1,195.7	5.8
EMEA	142.7		128.4		11.1	433.9		410.5		5.7
Asia	93.2		82.0		13.6	258.6		227.8		13.5
OEM	82.3		71.3		15.5	243.4		199.0		22.4
Segment net revenues	$	746.4	$	686.8	8.7	$	2,200.6	$	2,033.0	8.2

22

Segment operating profit
	Three Months Ended					Nine Months Ended
	October 1, 2023		September 25, 2022		% Increase/(Decrease)	October 1, 2023		September 25, 2022		% Increase/ (Decrease)
Americas	$	126.3	$	107.2	17.9	$	341.3	$	318.5	7.1
EMEA	17.9		7.5		139.2	43.7		29.3		49.3
Asia	26.0		22.9		13.5	70.1		61.8		13.5
OEM	23.5		18.4		27.4	67.3		47.2		42.6
Segment operating profit (1)	$	193.7	$	156.0	24.2	$	522.4	$	456.8	14.4

(1)See Note 14 to our condensed consolidated financial statements included in this report for a reconciliation of segment operating profit to our condensed consolidated income from continuing operations before interest and taxes.

Comparison of the three and nine months ended October 1, 2023 and September 25, 2022

Americas

Americas net revenues for the three months ended October 1, 2023 increased $23.1 million, or 5.7%, compared to the prior year period, which was primarily attributable to a $20.6 million increase in sales of new products and price increases, partially offset by a $12.2 million decrease in sales volume of existing products.

Americas net revenues for the nine months ended October 1, 2023 increased $69.0 million, or 5.8%, compared to the prior year period, which was primarily attributable to a $120.6 million increase in sales of new products and price increases, partially offset by a $86.4 million decrease in sales volume of existing products, notwithstanding the impact of a five-day increase in the number of shipping days during the nine months ended October 1, 2023.

The increase in sales of new products and the decrease in sales of volumes of existing products in both periods primarily reflect the conversion to the next generation of an existing product.

Americas operating profit for the three months ended October 1, 2023 increased $19.1 million, or 17.9%, compared to the prior year period, which was primarily attributable to a decrease in contingent consideration expense resulting from changes in the estimated fair value of our contingent consideration liabilities and an increase in gross profit resulting from higher sales and price increases. The increases in operating profit were partially offset by an increase in sales expenses to support higher sales.

Americas operating profit for the nine months ended October 1, 2023 increased $22.8 million, or 7.1%, compared to the prior year period, which was primarily attributable to an increase in gross profit resulting from higher sales and price increases and a decrease in contingent consideration expense resulting from changes in the estimated fair value of our contingent consideration liabilities. The increases in operating profit were partially offset by an increase in sales expenses to support higher sales and an increase in research and development expenses across certain of our product portfolios.

EMEA

EMEA net revenues for the three months ended October 1, 2023 increased $14.3 million, or 11.1%, compared to the prior year period, which was primarily attributable to $8.8 million in favorable fluctuations in foreign currency exchange rates and price increases.

EMEA net revenues for the nine months ended October 1, 2023 increased $23.4 million, or 5.7%, compared to the prior year period, which was primarily attributable to a $8.3 million increase in sales volume of existing products reflecting, in part, the impact of an increase in the number of shipping days, price increases and an increase in sales of new products.

EMEA operating profit for the three and nine months ended October 1, 2023 increased $10.4 million, or 139.2%, and $14.4 million, or 49.3%, respectively, compared to the prior year periods, which was primarily attributable to favorable fluctuations in foreign currency exchange rates and lower expenses related to the European Union Medical Device Regulation within research and development expenses.

Asia

Asia net revenues for the three months ended October 1, 2023 increased $11.2 million, or 13.6%, compared to the prior year period, which was primarily attributable to a $7.6 million increase in sales of new products, an

23

increase in sales volume of existing products and, to a lesser extent, price increases. The increases in net revenues were partially offset by unfavorable fluctuations in foreign currency exchange rates.

Asia net revenues for the nine months ended October 1, 2023 increased $30.8 million, or 13.5%, compared to the prior year period, which was primarily attributable to a $20.1 million increase in sales volume of existing products and a $17.2 million increase in sales of new products, partially offset by unfavorable fluctuations in foreign currency exchange rates.

Asia operating profit for the three and nine months ended October 1, 2023 increased $3.1 million, or 13.5%, and $8.3 million, or 13.5%, respectively, compared to the prior year periods, which was primarily attributable to an increase in gross profit resulting from higher sales, partially offset by unfavorable fluctuations in foreign currency exchange rates and an increase in sales expenses to support higher sales.

OEM

OEM net revenues for the three months ended October 1, 2023 increased $11.0 million, or 15.5%, compared to the prior year period, which was primarily attributable to price increases and a $3.9 million increase in sales volume of existing products.

OEM net revenues for the nine months ended October 1, 2023 increased $44.4 million, or 22.4%, compared to the prior year period, which was primarily attributable to a $26.6 million increase in sales volume of existing products and price increases.

OEM operating profit for the three and nine months ended October 1, 2023 increased $5.1 million, or 27.4%, and $20.1 million, or 42.6%, respectively, compared to the respective prior year periods, which was primarily attributable to an increase in gross profit resulting from price increases and higher sales, partially offset by higher research and development expenses.

Liquidity and Capital Resources

We believe our cash flow from operations, available cash and cash equivalents and borrowings under our revolving credit facility will enable us to fund our operating requirements, capital expenditures and debt obligations for the next 12 months and the foreseeable future. We have net cash provided by United States based operating activities as well as non-United States sources of cash available to help fund our debt service requirements in the United States. We manage our worldwide cash requirements by monitoring the funds available among our subsidiaries and determining the extent to which we can access those funds on a cost effective basis.

On October 4, 2023, the third day of our fourth quarter, the agreements related to our 2018 Cross-currency swap matured resulting in $43.0 million in cash settlement proceeds. On October 2, 2023, we executed new cross-currency swap agreements with six different financial institution counterparties to hedge against the effect of variability in the U.S. dollar to euro exchange rate. Under the terms of the swap agreements, we notionally exchanged $500 million at an interest rate of 4.63% for €474.7 million at an interest rate of 3.05%. The swap agreements, which expire on October 4, 2025, are designated as net investment hedges and require an exchange of the notional amounts upon expiration or the earlier termination of the agreements. We and the counterparties have agreed to effect the exchange through a net settlement. As a result, we may be required to pay (or be entitled to receive) an amount equal to the difference, on the expiration or earlier termination date, between the U.S. dollar equivalent of the €474.7 million notional amount and the $500 million notional amount. The swap agreements entail risk that the counterparties will not fulfill their obligations under the agreements. However, we believe the risk is reduced because we have entered into separate agreements with six different counterparties, all of whom are large, well-established financial institutions. Based on the U.S. dollar to euro currency exchange rate in effect on October 4, 2023, and assuming exchange rates remain constant throughout the two-year term of the swap agreements, we would realize a reduction in annual cash interest expense of $7.9 million.

Cash Flows

Net cash provided by operating activities from continuing operations was $372.4 million for the nine months ended October 1, 2023 as compared to $244.4 million for the nine months ended September 25, 2022. The $128.0 million increase was primarily attributable to favorable operating results, lower tax payments and favorable changes in working capital. The favorable changes in working capital were primarily driven by lower inventory purchases stemming from the build up on inventory in the prior year due to elevated global supply chain volatility.

24

Net cash used in investing activities from continuing operations was $57.7 million for the nine months ended October 1, 2023, and primarily consisted of $63.8 million of capital expenditures, partially offset by net interest proceeds on swaps designated as net investment hedges of $10.3 million.

Net cash provided by financing activities from continuing operations was $276.0 million for the nine months ended October 1, 2023, and primarily consisted of $324.4 million net proceeds from borrowings resulting from a $600 million draw on our Senior Credit facility to fund the fourth quarter acquisition of Palette, partially offset by previous payments against the Senior Credit facility. Net cash provided by financing activities for the year also reflects $47.9 million in dividend payments.

Borrowings

The indentures governing our 4.625% Senior Notes due 2027 (the “2027 Notes”) and 4.25% Senior Notes due 2028 (the "2028 Notes") contain covenants that, among other things and subject to certain exceptions, limit or restrict our ability, and the ability of our subsidiaries, to create liens; consolidate, merge or dispose of certain assets; and enter into sale leaseback transactions. As of October 1, 2023, we were in compliance with these requirements.

The obligations under our senior credit agreement (the "Credit Agreement"), the 2027 Notes and 2028 Notes are guaranteed (subject to certain exceptions) by substantially all of our material domestic subsidiaries, and the obligations under the Credit Agreement are (subject to certain exceptions and limitations) secured by a lien on substantially all of the assets owned by us and each guarantor.

Summarized Financial Information – Obligor Group

The 2027 Notes are issued by Teleflex Incorporated (the “Parent Company”), and payment of the Parent Company's obligations under the Senior Notes is guaranteed, jointly and severally, by an enumerated group of the Parent Company’s subsidiaries (each, a “Guarantor Subsidiary” and collectively, the “Guarantor Subsidiaries”). The guarantees are full and unconditional, subject to certain customary release provisions. Each Guarantor Subsidiary is directly or indirectly 100% owned by the Parent Company. Summarized financial information for the Parent and Guarantor Subsidiaries (collectively, the “Obligor Group”) as of October 1, 2023 and December 31, 2022 and for the nine months ended October 1, 2023 is as follows:

	Nine Months Ended
	October 1, 2023
	Obligor Group		Intercompany		Obligor Group (excluding Intercompany)
Net revenue	$	1,610.6	$	220.0	$	1,390.6
Cost of goods sold	1,065.4		336.9		728.5
Gross profit	545.2		(116.9)		662.1
Income from continuing operations	151.6		75.8		75.8
Net income	150.4		75.8		74.6

	October 1, 2023						December 31, 2022
	Obligor Group		Intercompany		Obligor Group  (excluding Intercompany)		Obligor Group		Intercompany		Obligor Group  (excluding Intercompany)
Total current assets	$	1,580.0	$	156.2	$	1,423.8	$	878.3	$	110.5	$	767.8
Total assets	4,061.2		1,565.7		2,495.5		3,420.3		1,510.9		1,909.4
Total current liabilities	1,079.7		836.9		242.8		882.9		627.9		255.0
Total liabilities	3,668.4		952.1		2,716.3		3,168.0		712.3		2,455.7

The same accounting policies as described in Note 1 to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2022 are used by the Parent Company and each of its subsidiaries in connection with the summarized financial information presented above. The Intercompany column in the table above represents transactions between and among the Obligor Group and non-guarantor subsidiaries (i.e. those subsidiaries of the Parent Company that have not guaranteed payment of the Senior Notes). Obligor investments in non-guarantor subsidiaries and any related activity are excluded from the financial information presented above.

Critical Accounting Estimates

25

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates and assumptions.

In our Annual Report on Form 10-K for the year ended December 31, 2022, we provided disclosure regarding our critical accounting estimates, which are reflective of significant judgments and uncertainties, are important to the presentation of our financial condition and results of operations and could potentially result in materially different results under different assumptions and conditions.

New Accounting Standards

See Note 2 to the condensed consolidated financial statements included in this report for a discussion of recently issued accounting guidance, including estimated effects, if any, of adoption of the guidance on our financial statements.

Forward-Looking Statements

All statements made in this Quarterly Report on Form 10-Q, other than statements of historical fact, are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “will,” “would,” “should,” “guidance,” “potential,” “continue,” “project,” “forecast,” “confident,” “prospects” and similar expressions typically are used to identify forward-looking statements. Forward-looking statements are based on the then-current expectations, beliefs, assumptions, estimates and forecasts about our business and the industry and markets in which we operate. These statements are not guarantees of future performance and are subject to risks and uncertainties, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or implied by these forward-looking statements due to a number of factors, including changes in business relationships with and purchases by or from major customers or suppliers; delays or cancellations in shipments; demand for and market acceptance of new and existing products; the impact of inflation and disruptions in our global supply chain on us and our suppliers (particularly sole-source suppliers and providers of sterilization services), including fluctuations in the cost and availability of resins and other raw materials, as well as certain components, used in the production or sterilization of our products, transportation constraints and delays, product shortages, energy shortages or increased energy costs, labor shortages in the United States and elsewhere, and increased operating and labor costs; our inability to integrate acquired businesses into our operations, realize planned synergies and operate such businesses profitably in accordance with our expectations; our inability to effectively execute our restructuring programs; our inability to realize anticipated savings resulting from restructuring plans and programs; the impact of enacted healthcare reform legislation and proposals to amend, replace or repeal the legislation; changes in Medicare, Medicaid and third party coverage and reimbursements; the impact of tax legislation and related regulations; competitive market conditions and resulting effects on revenues and pricing; global economic factors, including currency exchange rates, interest rates, trade disputes, sovereign debt issues, and international conflicts and hostilities, such as the ongoing conflicts in Ukraine and Israel; public health epidemics including the novel coronavirus (referred to as COVID-19); difficulties entering new markets; and general economic conditions. For a further discussion of the risks relating to our business, see Item 1A, Risk Factors, in our Annual Report on Form 10-K for the year ended December 31, 2022. We expressly disclaim any obligation to update these forward-looking statements, except as otherwise explicitly stated by us or as required by law or regulation.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

There have been no material changes to the information set forth in Part II, Item 7A of our Annual Report on Form 10-K for the year ended December 31, 2022.

Item 4. Controls and Procedures

(a) Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report are functioning effectively to provide reasonable assurance that the information required to be disclosed by us in reports filed under the Securities Exchange Act of 1934 is (i) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to our management, including the Chief Executive Officer and Chief

26

Financial Officer, as appropriate to allow timely decisions regarding disclosure. A controls system cannot provide absolute assurance that the objectives of the controls system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected.

(b) Change in Internal Control over Financial Reporting

No change in our internal control over financial reporting occurred during our most recently completed fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

27

PART II — OTHER INFORMATION

Item 1. Legal Proceedings

We are party to various lawsuits and claims arising in the normal course of business. These lawsuits and claims include actions involving product liability and product warranty, commercial disputes, intellectual property, contract, employment, environmental and other matters. As of October 1, 2023 and December 31, 2022, we had accrued liabilities of approximately $0.6 million and $0.5 million, respectively, in connection with these matters, representing our best estimate of the cost within the range of estimated possible loss that will be incurred to resolve these matters. Based on information currently available, advice of counsel, established reserves and other resources, we do not believe that the outcome of any outstanding lawsuits or claims is likely to be, individually or in the aggregate, material to our business, financial condition, results of operations or liquidity. However, in the event of unexpected further developments, it is possible that the ultimate resolution of these matters, or other similar matters, if unfavorable, may be materially adverse to our business, financial condition, results of operations or liquidity.

Item 1A. Risk Factors

See the information set forth in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2022. There have been no significant changes in risk factors for the quarter ended October 1, 2023.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Not applicable.

Item 3. Defaults Upon Senior Securities

Not applicable.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

Rule 10b5-1 Trading Plans

During the quarter ended October 1, 2023, none of our directors or executive officers entered into, modified or terminated, contracts, instructions or written plans for the sale or purchase of our securities that were intended to satisfy the affirmative defense conditions of Rule 10b5-1.

Certificate of Incorporation

At our 2023 Annual Meeting of Stockholders held on May 5, 2023 (the “2023 Annual Meeting”), our stockholders approved, among other things, proposals to (i) amend our Amended and Restated Certificate of Incorporation to eliminate supermajority voting provisions; and (ii) approve our 2023 Stock Incentive Plan (collectively, the "2023 Stockholder Actions"). The 2023 Stockholder Actions are described more fully in our definitive proxy statement for the 2023 Annual Meeting, filed with the SEC on March 31, 2023, and the voting results from the meeting, which were overwhelmingly in favor of both of the 2023 Stockholder Actions, are set forth in our Current Report on Form 8-K filed with the SEC on May 11, 2023. The record date established for the 2023 Annual Meeting was March 3, 2023, which exceeded by one business day the maximum of 60 days by which a record date is permitted to precede a meeting of stockholders under the Delaware General Corporation Law (the “DGCL”) and our Amended and Restated Bylaws. In August 2023, we filed a petition in the Delaware Court of Chancery pursuant to Section 205 of the DGCL seeking an order validating and declaring effective the 2023 Stockholder Actions. On September 18, 2023, the Court of Chancery issued an order approving our petition in full.

28

Item 6. Exhibits

The following exhibits are filed as part of, or incorporated by reference into, this report:

 

Exhibit No.		Description
31.1	—	Certification of Chief Executive Officer, pursuant to Rule 13a–14(a) under the Securities Exchange Act of 1934.
31.2	—	Certification of Chief Financial Officer, pursuant to Rule 13a–14(a) under the Securities Exchange Act of 1934.
32.1	—	Certification of Chief Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2	—	Certification of Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.1	—	The following materials from our Quarterly Report on Form 10-Q for the quarter ended October 1, 2023, formatted in inline XBRL (eXtensible Business Reporting Language): (i) Cover Page; (ii) the Condensed Consolidated Statements of Income for the three and nine months ended October 1, 2023 and September 25, 2022; (iii) the Condensed Consolidated Statements of Comprehensive Income for the three and nine months ended October 1, 2023 and September 25, 2022; (iv) the Condensed Consolidated Balance Sheets as of October 1, 2023 and December 31, 2022; (v) the Condensed Consolidated Statements of Cash Flows for the nine months ended October 1, 2023 and September 25, 2022; (vi) the Condensed Consolidated Statements of Changes in Equity for the three and nine months ended October 1, 2023 and September 25, 2022; and (vii) Notes to Condensed Consolidated Financial Statements.
104.1	—	The cover page of the Company's Quarterly Report on Form 10-Q for the quarter ended October 1, 2023, formatted in inline XBRL (included in Exhibit 101.1).

____________________________________

29

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

TELEFLEX INCORPORATED
By:	/s/ Liam J. Kelly
	Liam J. Kelly President and Chief Executive Officer (Principal Executive Officer)
By:	/s/ Thomas E. Powell
	Thomas E. Powell Executive Vice President and Chief Financial Officer (Principal Financial Officer)

Dated: November 3, 2023

30

EX-31.1

Exhibit 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

I, Liam J. Kelly, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Teleflex Incorporated;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 3, 2023	/s/ Liam J. Kelly
	Liam J. Kelly
	President and Chief Executive Officer

EX-31.2

Exhibit 31.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

I, Thomas E. Powell, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Teleflex Incorporated;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 3, 2023	/s/ Thomas E. Powell
	Thomas E. Powell
	Executive Vice President and Chief Financial Officer

EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO

RULE 13a-14(b) UNDER THE

SECURITIES EXCHANGE ACT OF 1934

In connection with the Quarterly Report of Teleflex Incorporated (the “Company”) on Form 10-Q for the period ending October 1, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Liam J. Kelly, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial position and results of operations of the Company.

Date: November 3, 2023	/s/ Liam J. Kelly
	Liam J. Kelly President and Chief Executive Officer

EX-32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO

RULE 13a-14(b) UNDER THE

SECURITIES EXCHANGE ACT OF 1934

In connection with the Quarterly Report of Teleflex Incorporated (the “Company”) on Form 10-Q for the period ending October 1, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Thomas E. Powell, Executive Vice President and Chief Financial Officer, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial position and results of operations of the Company.

Date: November 3, 2023	/s/ Thomas E. Powell
	Thomas E. Powell Executive Vice President and Chief Financial Officer

XML

Cover Page - shares	9 Months Ended
	Oct. 01, 2023	Oct. 31, 2023
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Oct. 01, 2023
Document Transition Report	false
Entity File Number	1-5353
Entity Registrant Name	TELEFLEX INCORPORATED
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	23-1147939
Entity Address, Address Line One	550 E. Swedesford Rd., Suite 400
Entity Address, City or Town	Wayne
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	19087
City Area Code	610
Local Phone Number	225-6800
Title of 12(b) Security	Common Stock, par value $1.00 per share
Trading Symbol	TFX
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Smaller Reporting Company	false
Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		46,992,664
Amendment Flag	false
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q3
Entity Central Index Key	0000096943
Current Fiscal Year End Date	--12-31

XML

CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 01, 2023	Sep. 25, 2022	Oct. 01, 2023	Sep. 25, 2022
Income Statement [Abstract]
Net revenues	$ 746,389	$ 686,788	$ 2,200,580	$ 2,033,045
Cost of goods sold	330,078	312,833	985,066	924,024
Gross profit	416,311	373,955	1,215,514	1,109,021
Selling, general and administrative expenses	213,194	209,616	669,216	630,373
Research and development expenses	37,576	37,770	118,493	111,064
Restructuring and impairment charges	231	628	3,960	2,950
Gains on sale of asset and business	0	(6,504)	0	(6,504)
Income from continuing operations before interest and taxes	165,310	132,445	423,845	371,138
Interest expense	23,192	13,375	59,291	35,212
Interest income	(7,487)	(126)	(9,486)	(577)
Income from continuing operations before taxes	149,605	119,196	374,040	336,503
Taxes on income from continuing operations	11,935	17,315	47,651	51,700
Income from continuing operations	137,670	101,881	326,389	284,803
Operating (loss) income from discontinued operations	(687)	19	(1,512)	(329)
Tax (benefit) expense on operating loss from discontinued operations	(157)	5	(346)	(76)
(Loss) income from discontinued operations	(530)	14	(1,166)	(253)
Net income	$ 137,140	$ 101,895	$ 325,223	$ 284,550
Basic:
Income from continuing operations (in dollars per share)	$ 2.93	$ 2.17	$ 6.95	$ 6.07
Loss from discontinued operations (in dollars per share)	(0.01)	0	(0.03)	0
Net income (in dollars per share)	2.92	2.17	6.92	6.07
Diluted:
Income from continuing operations (in dollars per share)	2.91	2.16	6.90	6.02
Loss from discontinued operations (in dollars per share)	(0.01)	0	(0.02)	(0.01)
Net income (in dollars per share)	$ 2.90	$ 2.16	$ 6.88	$ 6.01
Weighted average common shares outstanding
Basic (in shares)	46,992	46,906	46,974	46,894
Diluted (in shares)	47,299	47,263	47,304	47,337

XML

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 01, 2023	Sep. 25, 2022	Oct. 01, 2023	Sep. 25, 2022
Statement of Comprehensive Income [Abstract]
Net income	$ 137,140	$ 101,895	$ 325,223	$ 284,550
Other comprehensive (loss) income, net of tax:
Foreign currency translation, net of tax of $(4,667), $(12,477), $(434), and $(20,300) for the three and nine months periods, respectively	(29,417)	(55,194)	(13,368)	(123,576)
Pension and other postretirement benefit plans adjustment, net of tax of $(476), $(716), $(1,182), and $(1,862) for the three and nine months periods, respectively	1,543	2,195	3,951	5,807
Derivatives qualifying as hedges, net of tax of $(116), $(196), $334, and $(330) for the three and nine months periods, respectively	(2,412)	2,502	789	5,536
Other comprehensive (loss) income, net of tax:	(30,286)	(50,497)	(8,628)	(112,233)
Comprehensive income	$ 106,854	$ 51,398	$ 316,595	$ 172,317

XML

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 01, 2023	Sep. 25, 2022	Oct. 01, 2023	Sep. 25, 2022
Statement of Comprehensive Income [Abstract]
Foreign currency translation, tax	$ (4,667)	$ (12,477)	$ (434)	$ (20,300)
Pension and other postretirement benefits plans adjustment, tax	(476)	(716)	(1,182)	(1,862)
Derivatives qualifying as hedges, tax	$ (116)	$ (196)	$ 334	$ (330)

XML

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Oct. 01, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 881,499	$ 292,034
Accounts receivable, net	425,194	408,834
Inventories	625,075	578,507
Prepaid expenses and other current assets	138,657	125,084
Prepaid taxes	26,846	6,524
Total current assets	2,097,271	1,410,983
Property, plant and equipment, net	464,467	447,205
Operating lease assets	123,604	131,211
Goodwill	2,528,305	2,536,730
Intangible assets, net	2,180,539	2,306,165
Deferred tax assets	6,167	6,402
Other assets	93,281	89,367
Total assets	7,493,634	6,928,063
Current liabilities
Current borrowings	87,500	87,500
Accounts payable	130,686	126,807
Accrued expenses	133,067	140,644
Payroll and benefit-related liabilities	127,101	133,092
Accrued interest	17,428	5,332
Income taxes payable	24,375	24,736
Other current liabilities	65,265	63,381
Total current liabilities	585,422	581,492
Long-term borrowings	1,950,123	1,624,023
Deferred tax liabilities	389,080	388,886
Pension and postretirement benefit liabilities	30,051	31,394
Noncurrent liability for uncertain tax positions	6,545	5,805
Noncurrent operating lease liabilities	111,810	120,437
Other liabilities	106,555	154,058
Total liabilities	3,179,586	2,906,095
Commitments and contingencies
Total shareholders' equity	4,314,048	4,021,968
Total liabilities and shareholders' equity	$ 7,493,634	$ 6,928,063

XML

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Oct. 01, 2023	Sep. 25, 2022
Cash flows from operating activities of continuing operations:
Net income	$ 325,223	$ 284,550
Adjustments to reconcile net income to net cash provided by operating activities:
Loss from discontinued operations	1,166	253
Depreciation expense	52,687	49,076
Intangible asset amortization expense	125,230	121,904
Deferred financing costs and debt discount amortization expense	2,547	3,150
Changes in contingent consideration	(24,482)	237
Assets impairment charges	0	1,497
Stock-based compensation	22,135	19,804
Gain on sale of business	0	(6,504)
Deferred income taxes, net	2,076	63
Payments for contingent consideration	(289)	(2,983)
Interest benefit on swaps designated as net investment hedges	(15,459)	(15,677)
Other	4,743	(3,953)
Changes in assets and liabilities, net of effects of acquisitions and disposals:
Accounts receivable	(18,313)	(36,402)
Inventories	(50,702)	(85,293)
Prepaid expenses and other assets	7,487	21,298
Accounts payable, accrued expenses and other liabilities	(16,674)	(26,726)
Income taxes receivable and payable, net	(45,014)	(79,879)
Net cash provided by operating activities from continuing operations	372,361	244,415
Cash flows from investing activities of continuing operations:
Expenditures for property, plant and equipment	(63,768)	(52,648)
Proceeds from sale of business and assets	0	12,434
Payments for businesses and intangibles acquired, net of cash acquired	(205)	(27,308)
Net interest proceeds on swaps designated as net investment hedges	10,275	10,314
Proceeds from sales of investments	7,300	7,300
Purchase of investments	(11,300)	(7,300)
Net cash used in investing activities from continuing operations	(57,698)	(57,208)
Cash flows from financing activities of continuing operations:
Proceeds from new borrowings	646,000	0
Reduction in borrowings	(321,625)	(144,250)
Net proceeds (payments) from share based compensation plans and related tax impacts	534	(4,398)
Payments for contingent consideration	(949)	(3,885)
Dividends paid	(47,919)	(47,840)
Net cash provided by (used in) financing activities from continuing operations	276,041	(200,373)
Cash flows from discontinued operations:
Net cash used in operating activities	(579)	(482)
Net cash used in discontinued operations	(579)	(482)
Effect of exchange rate changes on cash and cash equivalents	(660)	(34,177)
Net increase (decrease) in cash and cash equivalents	589,465	(47,825)
Cash and cash equivalents at the beginning of the period	292,034	445,084
Cash and cash equivalents at the end of the period	$ 881,499	$ 397,259

XML

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid In Capital	Retained Earnings	Accumulated Other Comprehensive Loss	Treasury Stock
Common stock, shares, issued, beginning balance (in shares) at Dec. 31, 2021		47,929
Beginning balance at Dec. 31, 2021	$ 3,754,748	$ 47,929	$ 693,090	$ 3,517,954	$ (346,959)	$ (157,266)
Treasury stock, common, shares beginning balance (in shares) at Dec. 31, 2021						1,069
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	77,141			77,141
Cash dividends	(15,946)			(15,946)
Other comprehensive income (loss)	(21,286)				(21,286)
Shares issued under compensation plans (in shares)		5				27
Shares issued under compensation plans	(51)	$ 5	(950)			$ 894
Deferred compensation	928		100			$ 828
Deferred compensation (in shares)						(5)
Common stock, shares, issued, ending balance (in shares) at Mar. 27, 2022		47,934
Ending balance at Mar. 27, 2022	3,795,534	$ 47,934	692,240	3,579,149	(368,245)	$ (155,544)
Treasury stock, common, shares ending balance (in shares) at Mar. 27, 2022						1,037
Common stock, shares, issued, beginning balance (in shares) at Dec. 31, 2021		47,929
Beginning balance at Dec. 31, 2021	3,754,748	$ 47,929	693,090	3,517,954	(346,959)	$ (157,266)
Treasury stock, common, shares beginning balance (in shares) at Dec. 31, 2021						1,069
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	284,550
Other comprehensive income (loss)	(112,233)
Common stock, shares, issued, ending balance (in shares) at Sep. 25, 2022		47,941
Ending balance at Sep. 25, 2022	3,895,161	$ 47,941	707,060	3,754,664	(459,192)	$ (155,312)
Treasury stock, common, shares ending balance (in shares) at Sep. 25, 2022						1,034
Common stock, shares, issued, beginning balance (in shares) at Mar. 27, 2022		47,934
Beginning balance at Mar. 27, 2022	3,795,534	$ 47,934	692,240	3,579,149	(368,245)	$ (155,544)
Treasury stock, common, shares beginning balance (in shares) at Mar. 27, 2022						1,037
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	105,514			105,514
Cash dividends	(15,946)			(15,946)
Other comprehensive income (loss)	(40,450)				(40,450)
Shares issued under compensation plans (in shares)		6				2
Shares issued under compensation plans	8,075	$ 6	7,918			$ 151
Deferred compensation	3		(2)			5
Common stock, shares, issued, ending balance (in shares) at Jun. 26, 2022		47,940
Ending balance at Jun. 26, 2022	3,852,730	$ 47,940	700,156	3,668,717	(408,695)	$ (155,388)
Treasury stock, common, shares ending balance (in shares) at Jun. 26, 2022						1,035
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	101,895			101,895
Cash dividends	(15,948)			(15,948)
Other comprehensive income (loss)	(50,497)				(50,497)
Shares issued under compensation plans (in shares)		1				1
Shares issued under compensation plans	6,981	$ 1	6,904			$ 76
Common stock, shares, issued, ending balance (in shares) at Sep. 25, 2022		47,941
Ending balance at Sep. 25, 2022	3,895,161	$ 47,941	707,060	3,754,664	(459,192)	$ (155,312)
Treasury stock, common, shares ending balance (in shares) at Sep. 25, 2022						1,034
Common stock, shares, issued, beginning balance (in shares) at Dec. 31, 2022		47,957
Beginning balance at Dec. 31, 2022	4,021,968	$ 47,957	715,118	3,817,304	(403,522)	$ (154,889)
Treasury stock, common, shares beginning balance (in shares) at Dec. 31, 2022						1,032
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	76,748			76,748
Cash dividends	(15,969)			(15,969)
Other comprehensive income (loss)	22,191				22,191
Shares issued under compensation plans (in shares)		18				19
Shares issued under compensation plans	4,990	$ 18	2,333			$ 2,639
Deferred compensation	325		324			$ 1
Deferred compensation (in shares)						(6)
Common stock, shares, issued, ending balance (in shares) at Apr. 02, 2023		47,975
Ending balance at Apr. 02, 2023	4,110,253	$ 47,975	717,775	3,878,083	(381,331)	$ (152,249)
Treasury stock, common, shares ending balance (in shares) at Apr. 02, 2023						1,007
Common stock, shares, issued, beginning balance (in shares) at Dec. 31, 2022		47,957
Beginning balance at Dec. 31, 2022	4,021,968	$ 47,957	715,118	3,817,304	(403,522)	$ (154,889)
Treasury stock, common, shares beginning balance (in shares) at Dec. 31, 2022						1,032
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	325,223
Other comprehensive income (loss)	(8,628)
Common stock, shares, issued, ending balance (in shares) at Oct. 01, 2023		47,999
Ending balance at Oct. 01, 2023	4,314,048	$ 47,999	735,752	4,094,608	(412,150)	$ (152,161)
Treasury stock, common, shares ending balance (in shares) at Oct. 01, 2023						1,006
Common stock, shares, issued, beginning balance (in shares) at Apr. 02, 2023		47,975
Beginning balance at Apr. 02, 2023	4,110,253	$ 47,975	717,775	3,878,083	(381,331)	$ (152,249)
Treasury stock, common, shares beginning balance (in shares) at Apr. 02, 2023						1,007
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	111,335			111,335
Cash dividends	(15,972)			(15,972)
Other comprehensive income (loss)	(533)				(533)
Shares issued under compensation plans (in shares)		23
Shares issued under compensation plans	10,009	$ 23	9,920			$ 66
Common stock, shares, issued, ending balance (in shares) at Jul. 02, 2023		47,998
Ending balance at Jul. 02, 2023	4,215,092	$ 47,998	727,695	3,973,446	(381,864)	$ (152,183)
Treasury stock, common, shares ending balance (in shares) at Jul. 02, 2023						1,007
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	137,140			137,140
Cash dividends	(15,978)			(15,978)
Other comprehensive income (loss)	(30,286)				(30,286)
Shares issued under compensation plans (in shares)		1				1
Shares issued under compensation plans	8,080	$ 1	8,057			$ 22
Common stock, shares, issued, ending balance (in shares) at Oct. 01, 2023		47,999
Ending balance at Oct. 01, 2023	$ 4,314,048	$ 47,999	$ 735,752	$ 4,094,608	$ (412,150)	$ (152,161)
Treasury stock, common, shares ending balance (in shares) at Oct. 01, 2023						1,006

XML

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Parenthetical) - $ / shares	3 Months Ended
	Oct. 01, 2023	Jul. 02, 2023	Apr. 02, 2023	Sep. 25, 2022	Jun. 26, 2022	Mar. 27, 2022
Statement of Stockholders' Equity [Abstract]
Dividends per share (in dollars per share)	$ 0.34	$ 0.34	$ 0.34	$ 0.34	$ 0.34	$ 0.34

XML

Basis of presentation

9 Months Ended

Oct. 01, 2023

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Basis of presentation

Basis of presentation

The accompanying unaudited condensed consolidated financial statements of Teleflex Incorporated and its subsidiaries (“we,” “us,” “our" and “Teleflex”) are prepared on the same basis as its annual consolidated financial statements.

In the opinion of management, the financial statements reflect all adjustments, which are of a normal recurring nature, necessary for the fair statement of the financial statements for interim periods in accordance with accounting principles generally accepted in the United States of America ("GAAP") and Rule 10-01 of Securities and Exchange Commission ("SEC") Regulation S-X, which sets forth the instructions for the form and content of presentation of financial statements included in Form 10-Q. The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The results of operations for the periods reported are not necessarily indicative of those that may be expected for a full year.

In accordance with applicable accounting standards and as permitted by Rule 10-01 of Regulation S-X, the accompanying condensed consolidated financial statements do not include all of the information and footnote disclosures that are required to be included in our annual consolidated financial statements. Therefore, our quarterly condensed consolidated financial statements should be read in conjunction with our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2022.

XML

Recently issued accounting standards	9 Months Ended
	Oct. 01, 2023
Accounting Standards Update and Change in Accounting Principle [Abstract]
Recently issued accounting standards	Recently issued accounting standardsFrom time to time, new accounting guidance is issued by the FASB or other standard setting bodies that is adopted by us as of the effective date or, in some cases where early adoption is permitted, in advance of the effective date. We have assessed the recently issued guidance that is not yet effective and believe the new guidance will not have a material impact on the consolidated results of operations, cash flows or financial position.

XML

Net revenues

9 Months Ended

Oct. 01, 2023

Revenue from Contract with Customer [Abstract]

Net revenues

Net revenuesWe primarily generate revenue from the sale of medical devices including single use disposable devices and, to a lesser extent, reusable devices, instruments and capital equipment. Revenue is recognized when obligations under the terms of a contract with our customer are satisfied; this occurs upon the transfer of control of the products. Generally, transfer of control to the customer occurs at the point in time when our products are shipped from the manufacturing or distribution facility. For our Original Equipment and Development Services ("OEM") segment, most revenue is recognized over time because the OEM segment generates revenue from the sale of custom products that have no alternative use and we have an enforceable right to payment to the extent that performance has been completed. We market and sell products through our direct sales force and distributors to customers within the following end markets: (1) hospitals and healthcare providers; (2) other medical device manufacturers; and (3) home care providers, which constituted 87%, 11% and 2% of consolidated net revenues, respectively, for the nine months ended October 1, 2023. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring goods. With respect to the custom products sold in the OEM segment, revenue is measured using the units produced output method. Payment is generally due 30 days from the date of invoice.

The following table disaggregates revenue by global product category for the three and nine months ended October 1, 2023 and September 25, 2022.

	Three Months Ended				Nine Months Ended
	October 1, 2023		September 25, 2022		October 1, 2023		September 25, 2022
Vascular access	$	169,919	$	167,147	$	521,356	$	497,188
Anesthesia	97,612		97,608		291,786		289,260
Interventional	134,089		108,738		375,766		319,939
Surgical	112,805		93,124		317,781		282,468
Interventional urology	73,622		78,969		226,819		233,682
OEM	82,309		71,288		243,434		198,947
Other (1)	76,033		69,914		223,638		211,561
Net revenues (2)	$	746,389	$	686,788	$	2,200,580	$	2,033,045

(1)    Includes revenues generated from sales of our respiratory and urology products (other than interventional urology products).

(2)    The product categories listed above are presented on a global basis, while each of our reportable segments other than the OEM reportable segment are defined based on the geographic location of its operations; the OEM reportable segment operates globally. Each of the geographically based reportable segments includes net revenues from each of the non-OEM product categories listed above.

XML

Acquisitions and Divestiture

9 Months Ended

Oct. 01, 2023

Discontinued Operations and Disposal Groups [Abstract]

Acquisitions and Divestiture

Acquisitions and Divestiture

2023 acquisition

On July 25, 2023, we executed a definitive agreement to acquire Palette Life Sciences AB (“Palette”), a privately held medical device company that sells a portfolio of hyaluronic acid gel-based products primarily utilized in the treatment of urology diseases including a rectal spacing product used in connection with radiation therapy treatment of prostate cancer. The acquisition will complement our interventional urology product portfolio. On October 10, 2023, we completed the acquisition of Palette using borrowings under our revolving credit facility and cash on hand. Under the terms of the agreement, we acquired Palette for an initial cash payment of $600 million, with additional consideration of up to $50 million payable upon the achievement of certain commercial milestones.

2022 acquisition

In the fourth quarter of 2022, we completed the acquisition of Standard Bariatrics, Inc. (“Standard Bariatrics”), a privately-held medical device company that commercialized a powered stapling technology for bariatric surgery that complements our surgical product portfolio. Under the terms of the agreement, we acquired Standard Bariatrics for cash payments of $173 million, with the potential to make three milestone payments up to $130 million in the aggregate if certain commercial milestones are met.

Divestiture

On May 15, 2021, we entered into a definitive agreement to sell certain product lines within our global respiratory product portfolio (the "Divested respiratory business") to Medline Industries, Inc. (“Medline”) for consideration of $286.0 million, reduced by $12 million in working capital not transferring to Medline, which is subject to customary post close adjustments (the "Respiratory business divestiture"). In connection with the Respiratory business divestiture, we also entered into several ancillary agreements with Medline to help facilitate the transfer of the business, which provide for transition support, quality, supply and manufacturing services, including a manufacturing and supply transition agreement (the "MSTA").

On June 28, 2021, the first day of the third quarter of 2021, we completed the initial phase of the Respiratory business divestiture, pursuant to which we received cash proceeds of $259 million. The second phase of the Respiratory business divestiture will occur once we transfer certain additional manufacturing assets to Medline and is expected to occur prior to the end of 2023. We plan to recognize the remaining consideration, and any gain on sale resulting from the completion of the second phase of the divestiture, when it becomes realizable.

Net revenues attributed to services provided to Medline in accordance with the MSTA, which are presented within our Americas reporting segment, were $21.7 million and $62.7 million for the three and nine months ended October 1, 2023, respectively, and $19.1 million and $60.5 million for the three and nine months ended September 25, 2022, respectively.

XML

Restructuring and impairment charges

9 Months Ended

Oct. 01, 2023

Restructuring and Related Activities [Abstract]

Restructuring and impairment charges

Restructuring and impairment charges

Restructuring and impairment charges recognized for the three and nine months ended October 1, 2023 and September 25, 2022 consisted of the following:

Three Months Ended October 1, 2023	Termination Benefits		Other Costs (1)		Total
2023 Footprint realignment plan	$	1,296	$	—	$	1,296
2022 Restructuring plan	244		102		346
Respiratory divestiture plan	(851)		5		(846)
Other restructuring programs (2)	(612)		47		(565)
Restructuring charges	$	77	$	154	$	231

Three Months Ended September 25, 2022
	Termination Benefits		Other Costs (1)		Total
Respiratory divestiture plan	$	123	$	22	$	145
2019 Footprint realignment plan	(50)		16		(34)
2018 Footprint realignment plan	203		252		455
Other restructuring programs (3)	24		38		62
Restructuring charges	$	300	$	328	$	628

Nine Months Ended October 1, 2023
	Termination Benefits		Other Costs (1)		Total
2023 Footprint realignment plan	$	1,296	$	—	$	1,296
2022 Restructuring plan	3,361		313		3,674
Respiratory divestiture plan	(596)		17		(579)
Other restructuring programs (2)	(853)		422		(431)
Restructuring charges	$	3,208	$	752	$	3,960

Nine Months Ended September 25, 2022
	Termination Benefits		Other Costs (1)		Total
Respiratory divestiture plan	$	358	$	67	$	425
2019 Footprint realignment plan	(1,120)		61		(1,059)
2018 Footprint realignment plan	514		547		1,061
Other restructuring programs (3)	750		276		1,026
Restructuring charges	502		951		1,453
Asset impairment charges	—		1,497		1,497
Restructuring and impairment charges	$	502	$	2,448	$	2,950

(1) Other costs include facility closure, contract termination and other exit costs.

(2) Includes activity primarily related to a restructuring plan initiated in the first quarter of 2022 that is designed to relocate manufacturing operations at certain of our facilities (the "2022 Manufacturing relocation plan") and our 2014, 2018, and 2019 Footprint realignment plans.

(3) Includes activity primarily related to the 2022 Manufacturing relocation plan, the 2021 Restructuring plan and the 2014 Footprint realignment plan.

2023 Footprint Realignment plan

In September 2023, we initiated a restructuring plan primarily involving the relocation of certain manufacturing operations to existing lower-cost locations, the outsourcing of certain manufacturing processes and related workforce reductions (the "2023 Footprint realignment plan"). These actions are expected to be substantially completed by the end of 2027. The following table provides a summary of our estimates of restructuring and restructuring related charges by major type of expense associated with the 2023 Footprint realignment plan:

	Total estimated amount expected to be incurred
Plan expense estimates:	(Dollars in millions)
Restructuring charges (1)	$4 million to $6 million
Restructuring related charges (2)	$7 million to $9 million
Total restructuring and restructuring related charges	$11 million to $15 million

(1) Substantially all of the charges consist of employee termination benefit costs.

(2)Restructuring related charges represent costs that are directly related to the 2023 Footprint realignment plan and principally constitute costs to transfer manufacturing operations to existing lower-cost locations and project management costs. Substantially all of these charges are expected to be recognized within cost of goods sold.

We expect substantially all of the restructuring and restructuring related charges will result in future cash outlays, the majority of which will be made between 2024 and 2025. Additionally, we expect to incur $2 million to $3 million in aggregate capital expenditures under the plan, which are expected to be incurred mostly in 2024.

As of October 1, 2023, we maintain a restructuring reserve of $1.3 million in connection with this plan, all of which relate to termination benefits.

Respiratory divestiture plan

During 2021, in connection with the Respiratory business divestiture, we committed to a restructuring plan designed to separate the manufacturing operations to be transferred to Medline from those that will remain with Teleflex, which includes related workforce reductions (the “Respiratory divestiture plan”). The plan includes expanding certain of our existing locations to accommodate the transfer of capacity from the sites being transferred to Medline and replicating the manufacturing processes at alternate existing locations. We expect this plan will be substantially completed by the end of 2023. The following table provides a summary of our cost estimates by major type of expense associated with the Respiratory divestiture plan:

	Total estimated amount expected to be incurred
Plan expense estimates:	(Dollars in millions)
Restructuring charges (1)	$3 million to $3 million
Restructuring related charges (2)	$19 million to $21 million
Total restructuring and restructuring related charges	$22 million to $24 million

(1) Substantially all of the charges consist of employee termination benefit costs.

(2)Consist of charges that are directly related to the Respiratory divestiture plan and principally constitute costs to transfer manufacturing operations to other locations and project management costs. Substantially all of the charges are expected to be recognized within costs of goods sold.

We expect substantially all of the restructuring and restructuring related charges will result in future cash outlays, and we expect to incur $22 million to $24 million in aggregate capital expenditures under the plan.

We recorded restructuring related charges with respect to the Respiratory divestiture plan of $1.6 million and $5.6 million for the three and nine months ended October 1, 2023, respectively, and $2.1 million and $6.5 million for the three and nine months ended September 25, 2022, respectively. The restructuring related charges were included within cost of goods sold.

As of October 1, 2023, we have incurred net aggregate restructuring expenses related to the Respiratory divestiture plan of $2.7 million. Additionally, as of October 1, 2023, we have incurred net aggregate restructuring related charges in connection with the Respiratory divestiture plan of $17.9 million, which were primarily included in cost of goods sold. As of October 1, 2023, we have a restructuring reserve of $2.5 million in connection with this plan.

2022 Restructuring plan

In November 2022, we initiated a strategic restructuring plan designed to improve operating performance and position the organization to deliver long-term durable growth by creating efficiencies that align with our high growth strategic objectives (the “2022 Restructuring plan”). The plan is substantially complete and as a result, we expect future restructuring expenses associated with the plan, if any, to be immaterial.

XML

Inventories

9 Months Ended

Oct. 01, 2023

Inventory Disclosure [Abstract]

Inventories

Inventories

Inventories as of October 1, 2023 and December 31, 2022 consisted of the following:

	October 1, 2023		December 31, 2022
Raw materials	$	186,216	$	186,641
Work-in-process	111,371		98,993
Finished goods	327,488		292,873
Inventories	$	625,075	$	578,507

XML

Goodwill and other intangible assets

9 Months Ended

Oct. 01, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and other intangible assets

Goodwill and other intangible assets

The following table provides information relating to changes in the carrying amount of goodwill by reportable operating segment for the nine months ended October 1, 2023:

	Americas		EMEA		Asia		OEM		Total
December 31, 2022	$	1,731,093	$	468,524	$	225,103	$	112,010	$	2,536,730
Currency translation adjustment	2,608		(4,011)		(7,022)		—		(8,425)
October 1, 2023	$	1,733,701	$	464,513	$	218,081	$	112,010	$	2,528,305

The gross carrying amount of, and accumulated amortization relating to, intangible assets as of October 1, 2023 and December 31, 2022 were as follows:

	Gross Carrying Amount				Accumulated Amortization
	October 1, 2023		December 31, 2022		October 1, 2023		December 31, 2022
Customer relationships	$	1,326,706	$	1,328,539	$	(542,216)	$	(497,335)
In-process research and development	26,979		27,075		—		—
Intellectual property	1,600,259		1,599,355		(714,308)		(646,643)
Distribution rights	23,087		23,115		(21,643)		(21,090)
Trade names	562,461		564,023		(80,787)		(71,128)
Non-compete agreements	21,311		21,429		(21,310)		(21,175)
	$	3,560,803	$	3,563,536	$	(1,380,264)	$	(1,257,371)

XML

Borrowings

9 Months Ended

Oct. 01, 2023

Debt Disclosure [Abstract]

Borrowings

BorrowingsOur borrowings at October 1, 2023 and December 31, 2022 were as follows:

	October 1, 2023		December 31, 2022
Senior Credit Facility:
Revolving credit facility, at a rate of 6.67% at October 1, 2023, due 2027	$	482,000	$	148,250
Term loan facility, at a rate of 6.67% at October 1, 2023, due 2027	490,625		500,000
4.625% Senior Notes due 2027	500,000		500,000
4.25% Senior Notes due 2028	500,000		500,000
Securitization program, at a rate of 6.29% at October 1, 2023	75,000		75,000
	2,047,625		1,723,250
Less: Unamortized debt issuance costs	(10,002)		(11,727)
	2,037,623		1,711,523
Current borrowings	(87,500)		(87,500)
Long-term borrowings	$	1,950,123	$	1,624,023

XML

Financial instruments

9 Months Ended

Oct. 01, 2023

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Financial instruments

Financial instruments

Foreign currency forward contracts

We use derivative instruments for risk management purposes. Foreign currency forward contracts designated as cash flow hedges are used to manage foreign currency transaction exposure. Foreign currency forward contracts not designated as hedges for accounting purposes are used to manage exposure related to near term foreign currency denominated monetary assets and liabilities. We enter into the non-designated foreign currency forward contracts for periods consistent with our currency translation exposures, which generally approximate one month. For the three and nine months ended October 1, 2023, we recognized a loss of $1.0 million and a gain of $1.0 million, respectively, related to non-designated foreign currency forward contracts. For the three and nine months ended September 25, 2022, we recognized losses of $1.0 million and $4.2 million, respectively, related to non-designated foreign currency forward contracts.

The total notional amount for all open foreign currency forward contracts designated as cash flow hedges as of October 1, 2023 and December 31, 2022 was $238.1 million and $184.8 million, respectively. The total notional amount for all open non-designated foreign currency forward contracts as of October 1, 2023 and December 31, 2022 was $140.3 million and $152.9 million, respectively. All open foreign currency forward contracts as of October 1, 2023 have durations of 12 months or less.

Cross-currency interest rate swaps

During 2019, we entered into cross-currency swap agreements with five different financial institution counterparties to hedge against the effect of variability in the U.S. dollar to euro exchange rate. Under the terms of the cross-currency swap agreements, we have notionally exchanged $250 million at an annual interest rate of 4.88% for €219.2 million at an annual interest rate of 2.46%. The swap agreements are designed as net investment hedges and expire on March 4, 2024.

During 2018, we entered into cross-currency swap agreements with six different financial institution counterparties to hedge against the effect of variability in the U.S. dollar to euro exchange rate (the "2018 Cross-currency swap"). Under the terms of the cross-currency swap agreements, we have notionally exchanged $500 million at an annual interest rate of 4.63% for €433.9 million at an annual interest rate of 1.94%. The swap agreements are designed as net investment hedges. For further discussion related to the 2018 Cross-currency swap refer to subsequent event section below.

The swap agreements described above require an exchange of the notional amounts upon expiration or earlier termination of the agreements. We and the counterparties have agreed to effect the exchange through a net settlement.

The cross-currency swaps are marked to market at each reporting date and any changes in fair value are recognized as a component of accumulated other comprehensive income (loss) ("AOCI"). The following table summarizes the foreign exchange gains and losses recognized within AOCI and the interest benefit recognized within interest expense related to cross currency swap for the three and nine months ended October 1, 2023 and September 25, 2022:

	Three Months Ended				Nine Months Ended
	October 1, 2023		September 25, 2022		October 1, 2023		September 25, 2022
Foreign exchange gain	$	15,756	$	42,189	$	1,466	$	68,643
Interest benefit	5,171		5,531		15,459		15,677

Subsequent event

On October 4, 2023, the third day of our fourth quarter, the agreements related to our 2018 Cross-currency swap matured resulting in $43.0 million in cash settlement proceeds. On October 2, 2023, we executed new cross-currency swap agreements with six different financial institution counterparties to hedge against the effect of variability in the U.S. dollar to euro exchange rate. Under the terms of the cross-currency swap agreements, we have notionally exchanged $500 million at an annual interest rate of 4.63% for €474.7 million at an annual interest rate of 3.05%. The swap agreements are designated as net investment hedges and expire on October 4, 2025.

Balance sheet presentation

The following table presents the locations in the condensed consolidated balance sheet and fair value of derivative financial instruments as of October 1, 2023 and December 31, 2022:

	October 1, 2023		December 31, 2022
	Fair Value
Asset derivatives:
Designated foreign currency forward contracts	$	4,288	$	3,154
Non-designated foreign currency forward contracts	158		41
Cross-currency interest rate swaps	67,500		48,503
Prepaid expenses and other current assets	71,946		51,698
Cross-currency interest rate swaps	—		11,912
Other assets	—		11,912
Total asset derivatives	$	71,946	$	63,610
Liability derivatives:
Designated foreign currency forward contracts	$	2,819	$	983
Non-designated foreign currency forward contracts	422		477
Other current liabilities	3,241		1,460
Total liability derivatives	$	3,241	$	1,460

See Note 11 for information on the location and amount of gains and losses attributable to derivatives that were reclassified from AOCI to expense (income), net of tax. There was no ineffectiveness related to our cash flow hedges during the three and nine months ended October 1, 2023 and September 25, 2022.

Trade receivables

The allowance for credit losses as of October 1, 2023 and December 31, 2022 was $9.1 million and $8.6 million, respectively. The current portion of the allowance for credit losses, which was $5.2 million and $4.9 million as of October 1, 2023 and December 31, 2022, respectively, was recognized as a reduction of accounts receivable, net.

XML

Fair value measurement

9 Months Ended

Oct. 01, 2023

Fair Value Disclosures [Abstract]

Fair value measurement

Fair value measurement

The following tables provide information regarding our financial assets and liabilities measured at fair value on a recurring basis as of October 1, 2023 and December 31, 2022:

	Total carrying  value at  October 1, 2023		Quoted prices in active markets (Level 1)		Significant other observable Inputs (Level 2)		Significant unobservable Inputs (Level 3)
Investments in marketable securities	$	4,761	$	4,761	$	—	$	—
Derivative assets	71,946		—		71,946		—
Derivative liabilities	3,241		—		3,241		—
Contingent consideration liabilities	18,302		—		—		18,302

	Total carrying value at December 31, 2022		Quoted prices in active markets (Level 1)		Significant other observable Inputs (Level 2)		Significant unobservable Inputs (Level 3)
Investments in marketable securities	$	10,097	$	10,097	$	—	$	—
Derivative assets	63,610		—		63,610		—
Derivative liabilities	1,460		—		1,460		—
Contingent consideration liabilities	44,022		—		—		44,022

Valuation Techniques

Our financial assets valued based upon Level 1 inputs are comprised of investments in marketable securities held in trust, which are available to satisfy benefit obligations under our benefit plans and other arrangements. The investment assets of the trust are valued using quoted market prices.

Our financial assets and liabilities valued based upon Level 2 inputs are comprised of foreign currency forward contracts and cross-currency interest rate swap agreements. We use foreign currency forwards and cross-currency interest rate swaps to manage foreign currency transaction exposure, as well as exposure to foreign currency denominated monetary assets and liabilities. We measure the fair value of the foreign currency forwards and cross-currency swaps by calculating the amount required to enter into offsetting contracts with similar remaining maturities, based on quoted market prices, and taking into account the creditworthiness of the counterparties.

Our financial liabilities valued based upon Level 3 inputs (inputs that are not observable in the market) are comprised of contingent consideration arrangements pertaining to our acquisitions.

Contingent consideration

Contingent consideration liabilities, which primarily consist of payment obligations that are contingent upon the achievement of revenue-based goals, but also can be based on other milestones such as regulatory approvals, are remeasured to fair value each reporting period using assumptions including estimated revenues (based on internal operational budgets and long-range strategic plans), discount rates, probability of payment and projected payment dates.

We determine the fair value of certain contingent consideration liabilities using a Monte Carlo simulation (which involves a simulation of future revenues during the earn-out period using management's best estimates) or discounted cash flow analysis. Increases in projected revenues, estimated cash flows and probabilities of payment may result in significantly higher fair value measurements; decreases in these items may have the opposite effect. Increases in the discount rates in periods prior to payment may result in significantly lower fair value measurements and decreases in the discount rates may have the opposite effect.

The table below provides additional information regarding the valuation technique and inputs used in determining the fair value of our significant contingent consideration liabilities.

Contingent Consideration Liability	Valuation Technique	Unobservable Input
Revenue-based
	Monte Carlo simulation	Revenue volatility	30.6	%
		Risk free rate	Cost of debt structure
		Projected year of payment	2024 - 2026

The following table provides information regarding changes in our contingent consideration liabilities for the three and nine months ended October 1, 2023:

	Contingent consideration
Balance – December 31, 2022	$	44,022
Payments	(1,238)
Revaluations	(24,482)
Balance – October 1, 2023	$	18,302

XML

Shareholders' equity

9 Months Ended

Oct. 01, 2023

Equity [Abstract]

Shareholders' equity

Shareholders' equity

Basic earnings per share is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted earnings per share is computed in the same manner except that the weighted average number of shares is increased to include dilutive securities. The following table provides a reconciliation of basic to diluted weighted average number of common shares outstanding:

	Three Months Ended		Nine Months Ended
	October 1, 2023	September 25, 2022	October 1, 2023	September 25, 2022
Basic	46,992	46,906	46,974	46,894
Dilutive effect of share-based awards	307	357	330	443
Diluted	47,299	47,263	47,304	47,337

The weighted average number of shares that were antidilutive and therefore excluded from the calculation of earnings per share were 0.8 million and 0.7 million for the three and nine months ended October 1, 2023, respectively, and 0.7 million and 0.5 million for the three and nine months ended September 25, 2022, respectively.

The following tables provide information relating to the changes in accumulated other comprehensive loss, net of tax, for the nine months ended October 1, 2023 and September 25, 2022:

	Cash Flow Hedges		Pension and Other Postretirement Benefit Plans		Foreign Currency Translation Adjustment		Accumulated Other Comprehensive (Loss) Income
Balance as of December 31, 2022	$	4,931	$	(135,799)	$	(272,654)	$	(403,522)
Other comprehensive income (loss) before reclassifications	9,109		(76)		(13,368)		(4,335)
Amounts reclassified from accumulated other comprehensive (loss) income	(8,320)		4,027		—		(4,293)
Net current-period other comprehensive income (loss)	789		3,951		(13,368)		(8,628)
Balance as of October 1, 2023	$	5,720	$	(131,848)	$	(286,022)	$	(412,150)

	Cash Flow Hedges		Pension and Other Postretirement Benefit Plans		Foreign Currency Translation Adjustment		Accumulated Other Comprehensive (Loss) Income
Balance as of December 31, 2021	$	1,081	$	(138,290)	$	(209,750)	$	(346,959)
Other comprehensive income (loss) before reclassifications	6,871		1,980		(123,576)		(114,725)
Amounts reclassified from accumulated other comprehensive (loss) income	(1,335)		3,827		—		2,492
Net current-period other comprehensive income (loss)	5,536		5,807		(123,576)		(112,233)
Balance as of September 25, 2022	$	6,617	$	(132,483)	$	(333,326)	$	(459,192)

The following table provides information relating to the location in the statements of operations and amount of reclassifications of losses/(gains) in accumulated other comprehensive (loss) income into (income) expense, net of tax, for the three and nine months ended October 1, 2023 and September 25, 2022:

	Three Months Ended				Nine Months Ended
	October 1, 2023		September 25, 2022		October 1, 2023		September 25, 2022
(Gains) Loss on foreign exchange contracts:
Cost of goods sold	$	(3,499)	$	(1,614)	$	(8,734)	$	(1,445)
Total before tax	(3,499)		(1,614)		(8,734)		(1,445)
Taxes	34		84		414		110
Net of tax	(3,465)		(1,530)		(8,320)		(1,335)
Amortization of pension and other postretirement benefit items (1):
Actuarial losses	1,851		1,758		5,986		5,747
Prior-service costs	(252)		(252)		(756)		(756)
Total before tax	1,599		1,506		5,230		4,991
Tax benefit	(368)		(352)		(1,203)		(1,164)
Net of tax	1,231		1,154		4,027		3,827
Total reclassifications, net of tax	$	(2,234)	$	(376)	$	(4,293)	$	2,492

(1) These accumulated other comprehensive (loss) income components are included in the computation of net benefit expense for pension and other postretirement benefit plans.

XML

Taxes on income from continuing operations

9 Months Ended

Oct. 01, 2023

Income Tax Disclosure [Abstract]

Taxes on income from continuing operations

Taxes on income from continuing operations

	Three Months Ended		Nine Months Ended
	October 1, 2023	September 25, 2022	October 1, 2023	September 25, 2022
Effective income tax rate	8.0%	14.5%	12.7%	15.4%

The effective income tax rates for the three and nine months ended October 1, 2023 were 8.0% and 12.7%, respectively. The effective income tax rates for the three and nine months ended October 1, 2023 reflect the tax impact of a non-taxable contingent consideration adjustment recognized in connection with a decrease in the estimated fair value of our contingent consideration liabilities and tax benefits related to the 2023 Footprint Realignment plan and the 2022 Restructuring plan. The effective income tax rates for all periods reflect a tax benefit from research and development credits.

XML

Commitments and contingent liabilities

9 Months Ended

Oct. 01, 2023

Commitments and Contingencies Disclosure [Abstract]

Commitments and contingent liabilities

Commitments and contingent liabilitiesEnvironmental: We are subject to contingencies as a result of environmental laws and regulations that in the future may require us to take further action to correct the effects on the environment of prior disposal practices or releases of chemical or petroleum substances by us or other parties. Much of this liability results from the U.S. Comprehensive Environmental Response, Compensation and Liability Act, often referred to as Superfund, the U.S. Resource Conservation and Recovery Act and similar state laws. These laws require us to undertake certain

investigative and remedial activities at sites where we conduct or once conducted operations or at sites where Company-generated waste was disposed.

Remediation activities vary substantially in duration and cost from site to site. These activities, and their associated costs, depend on the mix of unique site characteristics, evolving remediation technologies, the regulatory agencies involved and their enforcement policies, as well as the presence or absence of other potentially responsible parties. At October 1, 2023, we have recorded $2.5 million and $4.1 million in accrued liabilities and other liabilities, respectively, relating to these matters. Considerable uncertainty exists with respect to these liabilities and, if adverse changes in circumstances occur, the potential liability may exceed the amount accrued as of October 1, 2023. The time frame over which the accrued amounts may be paid out, based on past history, is estimated to be 10-15 years.

Legal matters: We are a party to various lawsuits and claims arising in the normal course of business. These lawsuits and claims include actions involving product liability, product warranty, commercial disputes, intellectual property, contract, employment, environmental and other matters. As of October 1, 2023, we have recorded accrued liabilities of $0.6 million in connection with such contingencies, representing our best estimate of the cost within the range of estimated possible losses that will be incurred to resolve these matters.

Based on information currently available, advice of counsel, established reserves and other resources, we do not believe that the outcome of any outstanding litigation and claims is likely to be, individually or in the aggregate, material to our business, financial condition, results of operations or liquidity. However, in the event of unexpected further developments, it is possible that the ultimate resolution of these matters, or other similar matters, if unfavorable, may be materially adverse to our business, financial condition, results of operations or liquidity. Legal costs such as outside counsel fees and expenses are charged to selling, general and administrative expenses in the period incurred.

Other: In 2015, the Italian parliament enacted legislation that, among other things, imposed a “payback” measure on medical device companies that supply goods and services to the Italian National Healthcare System. Under the measure, companies are required to make payments to the Italian government if medical device expenditures in a given year exceed regional expenditure ceilings established for that year. The payment amounts are calculated based on the amount by which the regional ceilings for the given year were exceeded. Considerable uncertainty exists related to the enforceability of and implementation process for the payback law. In response to decrees issued by the Italian Ministry of Health, the various Italian regions issued invoices to medical device companies, including Teleflex, under the payback measure in the fourth quarter of 2022 seeking payment with respect to excess expenditures for the years 2015 through 2018. Following the issuance of the invoices, we and numerous other medical device companies filed appeals with the Italian administrative courts challenging the enforceability of the payback measure, which appeals remain pending. As of October 1, 2023, our reserve for this matter was $12.9 million, of which $2.2 million was recorded as a reduction of revenue in 2023. If the payback was to ultimately be enforced in its existing form, we estimate that we would be required to remit payments in excess of our current reserve of up to $18.6 million.

On April 4, 2023, one of our Mexican subsidiaries received a notification from the Mexican Federal Tax Administration Service (“SAT”) setting forth its preliminary findings with respect to a foreign trade operations audit carried out by SAT for the period from July 1, 2017 to June 6, 2019. The preliminary findings stated that our Mexican subsidiary did not evidence the export of goods temporarily imported under Mexico’s Manufacturing, Maquila and Export Services Industries Program (“IMMEX Program”), therefore triggering the potential obligation for payment of import duties, value added tax, customs processing fees and other fines and penalties. In response to the notification, our Mexican subsidiary has requested that the matter be referred to the Procuraduría de la Defensa del Contribuyente, or “PRODECON,” (local tax ombudsperson) to help facilitate the process. In June, SAT was provided with the appropriate documentation evidencing the export of the goods in accordance with the requirements of the IMMEX Program.

While we cannot predict with certainty the outcome of this audit, based on currently known information, we do not believe a loss is either probable or estimable. Accordingly, no loss contingency has been recorded in our financial statements as of October 1, 2023 related to this matter. However, if the final resolution of the matter is not favorable to us, our Mexican subsidiary may be required to make payment of certain import duties, fines and surcharges, which could be material.

Tax audits and examinations: We are routinely subject to tax examinations by various tax authorities. As of October 1, 2023, the most significant tax examinations in process were in Ireland and Germany. We may establish reserves with respect to our uncertain tax positions, after we adjust the reserves to address developments with respect to our uncertain tax positions, including developments in these tax examinations. Accordingly, developments in tax audits and examinations, including resolution of uncertain tax positions, could result in increases or decreases to our recorded tax liabilities, which could impact our financial results.

XML

Segment information

9 Months Ended

Oct. 01, 2023

Segment Reporting [Abstract]

Segment information

Segment information

The following tables present our segment results for the three and nine months ended October 1, 2023 and September 25, 2022:

	Three Months Ended				Nine Months Ended
	October 1, 2023		September 25, 2022		October 1, 2023		September 25, 2022
Americas	$	428,206	$	405,038	$	1,264,714	$	1,195,739
EMEA	142,723		128,437		433,872		410,535
Asia	93,151		82,025		258,560		227,824
OEM	82,309		71,288		243,434		198,947
Net revenues	$	746,389	$	686,788	$	2,200,580	$	2,033,045

	Three Months Ended				Nine Months Ended
	October 1, 2023		September 25, 2022		October 1, 2023		September 25, 2022
Americas	$	126,340	$	107,180	$	341,261	$	318,548
EMEA	17,876		7,472		43,744		29,291
Asia	25,978		22,885		70,126		61,796
OEM	23,491		18,438		67,307		47,197
Total segment operating profit (1)	193,685		155,975		522,438		456,832
Unallocated expenses (2)	(28,375)		(23,530)		(98,593)		(85,694)
Income from continuing operations before interest and taxes	$	165,310	$	132,445	$	423,845	$	371,138

(1)Segment operating profit includes segment net revenues from external customers reduced by its standard cost of goods sold, adjusted for fixed manufacturing cost absorption variances, selling, general and administrative expenses, research and development expenses and an allocation of corporate expenses.

(2)Unallocated expenses primarily include manufacturing variances other than fixed manufacturing cost absorption variances and restructuring and impairment charges.

XML

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Oct. 01, 2023	Jul. 02, 2023	Apr. 02, 2023	Sep. 25, 2022	Jun. 26, 2022	Mar. 27, 2022	Oct. 01, 2023	Sep. 25, 2022
Pay vs Performance Disclosure
Net income	$ 137,140	$ 111,335	$ 76,748	$ 101,895	$ 105,514	$ 77,141	$ 325,223	$ 284,550

XML

Insider Trading Arrangements	3 Months Ended
	Oct. 01, 2023
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

XML

Recently issued accounting standards (Policies)

9 Months Ended

Oct. 01, 2023

Accounting Standards Update and Change in Accounting Principle [Abstract]

Basis of presentation

Basis of presentation

The accompanying unaudited condensed consolidated financial statements of Teleflex Incorporated and its subsidiaries (“we,” “us,” “our" and “Teleflex”) are prepared on the same basis as its annual consolidated financial statements.

In the opinion of management, the financial statements reflect all adjustments, which are of a normal recurring nature, necessary for the fair statement of the financial statements for interim periods in accordance with accounting principles generally accepted in the United States of America ("GAAP") and Rule 10-01 of Securities and Exchange Commission ("SEC") Regulation S-X, which sets forth the instructions for the form and content of presentation of financial statements included in Form 10-Q. The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The results of operations for the periods reported are not necessarily indicative of those that may be expected for a full year.

In accordance with applicable accounting standards and as permitted by Rule 10-01 of Regulation S-X, the accompanying condensed consolidated financial statements do not include all of the information and footnote disclosures that are required to be included in our annual consolidated financial statements. Therefore, our quarterly condensed consolidated financial statements should be read in conjunction with our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2022.

Recently issued accounting standards

Recently issued accounting standardsFrom time to time, new accounting guidance is issued by the FASB or other standard setting bodies that is adopted by us as of the effective date or, in some cases where early adoption is permitted, in advance of the effective date. We have assessed the recently issued guidance that is not yet effective and believe the new guidance will not have a material impact on the consolidated results of operations, cash flows or financial position.

XML

Net revenues (Tables)

9 Months Ended

Oct. 01, 2023

Revenue from Contract with Customer [Abstract]

Schedule of revenue by major customers by reporting segments

The following table disaggregates revenue by global product category for the three and nine months ended October 1, 2023 and September 25, 2022.

	Three Months Ended				Nine Months Ended
	October 1, 2023		September 25, 2022		October 1, 2023		September 25, 2022
Vascular access	$	169,919	$	167,147	$	521,356	$	497,188
Anesthesia	97,612		97,608		291,786		289,260
Interventional	134,089		108,738		375,766		319,939
Surgical	112,805		93,124		317,781		282,468
Interventional urology	73,622		78,969		226,819		233,682
OEM	82,309		71,288		243,434		198,947
Other (1)	76,033		69,914		223,638		211,561
Net revenues (2)	$	746,389	$	686,788	$	2,200,580	$	2,033,045

(1)    Includes revenues generated from sales of our respiratory and urology products (other than interventional urology products).

(2)    The product categories listed above are presented on a global basis, while each of our reportable segments other than the OEM reportable segment are defined based on the geographic location of its operations; the OEM reportable segment operates globally. Each of the geographically based reportable segments includes net revenues from each of the non-OEM product categories listed above.

XML

Restructuring and impairment charges (Tables)

9 Months Ended

Oct. 01, 2023

Restructuring and Related Activities [Abstract]

Restructuring and Other Impairment Charges

Restructuring and impairment charges recognized for the three and nine months ended October 1, 2023 and September 25, 2022 consisted of the following:

Three Months Ended October 1, 2023	Termination Benefits		Other Costs (1)		Total
2023 Footprint realignment plan	$	1,296	$	—	$	1,296
2022 Restructuring plan	244		102		346
Respiratory divestiture plan	(851)		5		(846)
Other restructuring programs (2)	(612)		47		(565)
Restructuring charges	$	77	$	154	$	231

Three Months Ended September 25, 2022
	Termination Benefits		Other Costs (1)		Total
Respiratory divestiture plan	$	123	$	22	$	145
2019 Footprint realignment plan	(50)		16		(34)
2018 Footprint realignment plan	203		252		455
Other restructuring programs (3)	24		38		62
Restructuring charges	$	300	$	328	$	628

Nine Months Ended October 1, 2023
	Termination Benefits		Other Costs (1)		Total
2023 Footprint realignment plan	$	1,296	$	—	$	1,296
2022 Restructuring plan	3,361		313		3,674
Respiratory divestiture plan	(596)		17		(579)
Other restructuring programs (2)	(853)		422		(431)
Restructuring charges	$	3,208	$	752	$	3,960

Nine Months Ended September 25, 2022
	Termination Benefits		Other Costs (1)		Total
Respiratory divestiture plan	$	358	$	67	$	425
2019 Footprint realignment plan	(1,120)		61		(1,059)
2018 Footprint realignment plan	514		547		1,061
Other restructuring programs (3)	750		276		1,026
Restructuring charges	502		951		1,453
Asset impairment charges	—		1,497		1,497
Restructuring and impairment charges	$	502	$	2,448	$	2,950

(1) Other costs include facility closure, contract termination and other exit costs.

(2) Includes activity primarily related to a restructuring plan initiated in the first quarter of 2022 that is designed to relocate manufacturing operations at certain of our facilities (the "2022 Manufacturing relocation plan") and our 2014, 2018, and 2019 Footprint realignment plans.

(3) Includes activity primarily related to the 2022 Manufacturing relocation plan, the 2021 Restructuring plan and the 2014 Footprint realignment plan.

Summary Of Current Cost Estimates By Major Type Of Cost Table

The following table provides a summary of our estimates of restructuring and restructuring related charges by major type of expense associated with the 2023 Footprint realignment plan:

	Total estimated amount expected to be incurred
Plan expense estimates:	(Dollars in millions)
Restructuring charges (1)	$4 million to $6 million
Restructuring related charges (2)	$7 million to $9 million
Total restructuring and restructuring related charges	$11 million to $15 million

(1) Substantially all of the charges consist of employee termination benefit costs.

(2)Restructuring related charges represent costs that are directly related to the 2023 Footprint realignment plan and principally constitute costs to transfer manufacturing operations to existing lower-cost locations and project management costs. Substantially all of these charges are expected to be recognized within cost of goods sold.

The following table provides a summary of our cost estimates by major type of expense associated with the Respiratory divestiture plan:

	Total estimated amount expected to be incurred
Plan expense estimates:	(Dollars in millions)
Restructuring charges (1)	$3 million to $3 million
Restructuring related charges (2)	$19 million to $21 million
Total restructuring and restructuring related charges	$22 million to $24 million

(1) Substantially all of the charges consist of employee termination benefit costs.

(2)Consist of charges that are directly related to the Respiratory divestiture plan and principally constitute costs to transfer manufacturing operations to other locations and project management costs. Substantially all of the charges are expected to be recognized within costs of goods sold.

XML

Inventories (Tables)

9 Months Ended

Oct. 01, 2023

Inventory Disclosure [Abstract]

Schedule of Inventory

Inventories as of October 1, 2023 and December 31, 2022 consisted of the following:

	October 1, 2023		December 31, 2022
Raw materials	$	186,216	$	186,641
Work-in-process	111,371		98,993
Finished goods	327,488		292,873
Inventories	$	625,075	$	578,507

XML

Goodwill and other intangible assets, net (Tables)

9 Months Ended

Oct. 01, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Goodwill

The following table provides information relating to changes in the carrying amount of goodwill by reportable operating segment for the nine months ended October 1, 2023:

	Americas		EMEA		Asia		OEM		Total
December 31, 2022	$	1,731,093	$	468,524	$	225,103	$	112,010	$	2,536,730
Currency translation adjustment	2,608		(4,011)		(7,022)		—		(8,425)
October 1, 2023	$	1,733,701	$	464,513	$	218,081	$	112,010	$	2,528,305

Schedule of Finite-Lived Intangible Assets

The gross carrying amount of, and accumulated amortization relating to, intangible assets as of October 1, 2023 and December 31, 2022 were as follows:

	Gross Carrying Amount				Accumulated Amortization
	October 1, 2023		December 31, 2022		October 1, 2023		December 31, 2022
Customer relationships	$	1,326,706	$	1,328,539	$	(542,216)	$	(497,335)
In-process research and development	26,979		27,075		—		—
Intellectual property	1,600,259		1,599,355		(714,308)		(646,643)
Distribution rights	23,087		23,115		(21,643)		(21,090)
Trade names	562,461		564,023		(80,787)		(71,128)
Non-compete agreements	21,311		21,429		(21,310)		(21,175)
	$	3,560,803	$	3,563,536	$	(1,380,264)	$	(1,257,371)

XML

Borrowings (Tables)

9 Months Ended

Oct. 01, 2023

Debt Disclosure [Abstract]

Components of Long-Term Debt

Our borrowings at October 1, 2023 and December 31, 2022 were as follows:

	October 1, 2023		December 31, 2022
Senior Credit Facility:
Revolving credit facility, at a rate of 6.67% at October 1, 2023, due 2027	$	482,000	$	148,250
Term loan facility, at a rate of 6.67% at October 1, 2023, due 2027	490,625		500,000
4.625% Senior Notes due 2027	500,000		500,000
4.25% Senior Notes due 2028	500,000		500,000
Securitization program, at a rate of 6.29% at October 1, 2023	75,000		75,000
	2,047,625		1,723,250
Less: Unamortized debt issuance costs	(10,002)		(11,727)
	2,037,623		1,711,523
Current borrowings	(87,500)		(87,500)
Long-term borrowings	$	1,950,123	$	1,624,023

XML

Financial instruments (Tables)

9 Months Ended

Oct. 01, 2023

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of foreign exchange gains and losses recognized within AOCI and the interest benefit recognized within interest expense

The following table summarizes the foreign exchange gains and losses recognized within AOCI and the interest benefit recognized within interest expense related to cross currency swap for the three and nine months ended October 1, 2023 and September 25, 2022:

	Three Months Ended				Nine Months Ended
	October 1, 2023		September 25, 2022		October 1, 2023		September 25, 2022
Foreign exchange gain	$	15,756	$	42,189	$	1,466	$	68,643
Interest benefit	5,171		5,531		15,459		15,677

Fair Values of Derivative Instruments Designated as Hedging Instruments

The following table presents the locations in the condensed consolidated balance sheet and fair value of derivative financial instruments as of October 1, 2023 and December 31, 2022:

	October 1, 2023		December 31, 2022
	Fair Value
Asset derivatives:
Designated foreign currency forward contracts	$	4,288	$	3,154
Non-designated foreign currency forward contracts	158		41
Cross-currency interest rate swaps	67,500		48,503
Prepaid expenses and other current assets	71,946		51,698
Cross-currency interest rate swaps	—		11,912
Other assets	—		11,912
Total asset derivatives	$	71,946	$	63,610
Liability derivatives:
Designated foreign currency forward contracts	$	2,819	$	983
Non-designated foreign currency forward contracts	422		477
Other current liabilities	3,241		1,460
Total liability derivatives	$	3,241	$	1,460

XML

Fair value measurement (Tables)

9 Months Ended

Oct. 01, 2023

Fair Value Disclosures [Abstract]

Financial assets and liabilities carried at fair value measured on recurring basis

The following tables provide information regarding our financial assets and liabilities measured at fair value on a recurring basis as of October 1, 2023 and December 31, 2022:

	Total carrying  value at  October 1, 2023		Quoted prices in active markets (Level 1)		Significant other observable Inputs (Level 2)		Significant unobservable Inputs (Level 3)
Investments in marketable securities	$	4,761	$	4,761	$	—	$	—
Derivative assets	71,946		—		71,946		—
Derivative liabilities	3,241		—		3,241		—
Contingent consideration liabilities	18,302		—		—		18,302

	Total carrying value at December 31, 2022		Quoted prices in active markets (Level 1)		Significant other observable Inputs (Level 2)		Significant unobservable Inputs (Level 3)
Investments in marketable securities	$	10,097	$	10,097	$	—	$	—
Derivative assets	63,610		—		63,610		—
Derivative liabilities	1,460		—		1,460		—
Contingent consideration liabilities	44,022		—		—		44,022

Schedule of Valuation Techniques

The table below provides additional information regarding the valuation technique and inputs used in determining the fair value of our significant contingent consideration liabilities.

Contingent Consideration Liability	Valuation Technique	Unobservable Input
Revenue-based
	Monte Carlo simulation	Revenue volatility	30.6	%
		Risk free rate	Cost of debt structure
		Projected year of payment	2024 - 2026

Reconciliation of Changes in Level 3 Financial Liabilities Measured at Fair Value on Recurring Basis

The following table provides information regarding changes in our contingent consideration liabilities for the three and nine months ended October 1, 2023:

	Contingent consideration
Balance – December 31, 2022	$	44,022
Payments	(1,238)
Revaluations	(24,482)
Balance – October 1, 2023	$	18,302

XML

Shareholders' equity (Tables)

9 Months Ended

Oct. 01, 2023

Equity [Abstract]

Reconciliation of Basic to Diluted Weighted Average Common Shares Outstanding

The following table provides a reconciliation of basic to diluted weighted average number of common shares outstanding:

	Three Months Ended		Nine Months Ended
	October 1, 2023	September 25, 2022	October 1, 2023	September 25, 2022
Basic	46,992	46,906	46,974	46,894
Dilutive effect of share-based awards	307	357	330	443
Diluted	47,299	47,263	47,304	47,337

Change in Accumulated Other Comprehensive Income (Loss)

The following tables provide information relating to the changes in accumulated other comprehensive loss, net of tax, for the nine months ended October 1, 2023 and September 25, 2022:

	Cash Flow Hedges		Pension and Other Postretirement Benefit Plans		Foreign Currency Translation Adjustment		Accumulated Other Comprehensive (Loss) Income
Balance as of December 31, 2022	$	4,931	$	(135,799)	$	(272,654)	$	(403,522)
Other comprehensive income (loss) before reclassifications	9,109		(76)		(13,368)		(4,335)
Amounts reclassified from accumulated other comprehensive (loss) income	(8,320)		4,027		—		(4,293)
Net current-period other comprehensive income (loss)	789		3,951		(13,368)		(8,628)
Balance as of October 1, 2023	$	5,720	$	(131,848)	$	(286,022)	$	(412,150)

	Cash Flow Hedges		Pension and Other Postretirement Benefit Plans		Foreign Currency Translation Adjustment		Accumulated Other Comprehensive (Loss) Income
Balance as of December 31, 2021	$	1,081	$	(138,290)	$	(209,750)	$	(346,959)
Other comprehensive income (loss) before reclassifications	6,871		1,980		(123,576)		(114,725)
Amounts reclassified from accumulated other comprehensive (loss) income	(1,335)		3,827		—		2,492
Net current-period other comprehensive income (loss)	5,536		5,807		(123,576)		(112,233)
Balance as of September 25, 2022	$	6,617	$	(132,483)	$	(333,326)	$	(459,192)

Reclassification of Gain/Losses into Income/Expense, Net of Tax

The following table provides information relating to the location in the statements of operations and amount of reclassifications of losses/(gains) in accumulated other comprehensive (loss) income into (income) expense, net of tax, for the three and nine months ended October 1, 2023 and September 25, 2022:

	Three Months Ended				Nine Months Ended
	October 1, 2023		September 25, 2022		October 1, 2023		September 25, 2022
(Gains) Loss on foreign exchange contracts:
Cost of goods sold	$	(3,499)	$	(1,614)	$	(8,734)	$	(1,445)
Total before tax	(3,499)		(1,614)		(8,734)		(1,445)
Taxes	34		84		414		110
Net of tax	(3,465)		(1,530)		(8,320)		(1,335)
Amortization of pension and other postretirement benefit items (1):
Actuarial losses	1,851		1,758		5,986		5,747
Prior-service costs	(252)		(252)		(756)		(756)
Total before tax	1,599		1,506		5,230		4,991
Tax benefit	(368)		(352)		(1,203)		(1,164)
Net of tax	1,231		1,154		4,027		3,827
Total reclassifications, net of tax	$	(2,234)	$	(376)	$	(4,293)	$	2,492

(1) These accumulated other comprehensive (loss) income components are included in the computation of net benefit expense for pension and other postretirement benefit plans.

XML

Taxes on income from continuing operations (Tables)

9 Months Ended

Oct. 01, 2023

Income Tax Disclosure [Abstract]

Effective Income Tax Rate

	Three Months Ended		Nine Months Ended
	October 1, 2023	September 25, 2022	October 1, 2023	September 25, 2022
Effective income tax rate	8.0%	14.5%	12.7%	15.4%

XML

Segment information (Tables)

9 Months Ended

Oct. 01, 2023

Segment Reporting [Abstract]

Segment Results

The following tables present our segment results for the three and nine months ended October 1, 2023 and September 25, 2022:

	Three Months Ended				Nine Months Ended
	October 1, 2023		September 25, 2022		October 1, 2023		September 25, 2022
Americas	$	428,206	$	405,038	$	1,264,714	$	1,195,739
EMEA	142,723		128,437		433,872		410,535
Asia	93,151		82,025		258,560		227,824
OEM	82,309		71,288		243,434		198,947
Net revenues	$	746,389	$	686,788	$	2,200,580	$	2,033,045

	Three Months Ended				Nine Months Ended
	October 1, 2023		September 25, 2022		October 1, 2023		September 25, 2022
Americas	$	126,340	$	107,180	$	341,261	$	318,548
EMEA	17,876		7,472		43,744		29,291
Asia	25,978		22,885		70,126		61,796
OEM	23,491		18,438		67,307		47,197
Total segment operating profit (1)	193,685		155,975		522,438		456,832
Unallocated expenses (2)	(28,375)		(23,530)		(98,593)		(85,694)
Income from continuing operations before interest and taxes	$	165,310	$	132,445	$	423,845	$	371,138

(1)Segment operating profit includes segment net revenues from external customers reduced by its standard cost of goods sold, adjusted for fixed manufacturing cost absorption variances, selling, general and administrative expenses, research and development expenses and an allocation of corporate expenses.

(2)Unallocated expenses primarily include manufacturing variances other than fixed manufacturing cost absorption variances and restructuring and impairment charges.

XML

Net revenues (Details) - Sales revenue, net - Customer concentration risk	9 Months Ended
	Oct. 01, 2023
Hospitals And Healthcare Providers
Concentration Risk [Line Items]
Percentage of total revenue	87.00%
Other Medical Device Manufacturers
Concentration Risk [Line Items]
Percentage of total revenue	11.00%
Home Care Providers
Concentration Risk [Line Items]
Percentage of total revenue	2.00%

XML

Net revenues - Other revenues (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 01, 2023	Sep. 25, 2022	Oct. 01, 2023	Sep. 25, 2022
Revenue, Major Customer [Line Items]
Net revenues	$ 746,389	$ 686,788	$ 2,200,580	$ 2,033,045
Vascular access
Revenue, Major Customer [Line Items]
Net revenues	169,919	167,147	521,356	497,188
Anesthesia
Revenue, Major Customer [Line Items]
Net revenues	97,612	97,608	291,786	289,260
Interventional
Revenue, Major Customer [Line Items]
Net revenues	134,089	108,738	375,766	319,939
Surgical
Revenue, Major Customer [Line Items]
Net revenues	112,805	93,124	317,781	282,468
Interventional urology
Revenue, Major Customer [Line Items]
Net revenues	73,622	78,969	226,819	233,682
OEM
Revenue, Major Customer [Line Items]
Net revenues	82,309	71,288	243,434	198,947
Other
Revenue, Major Customer [Line Items]
Net revenues	$ 76,033	$ 69,914	$ 223,638	$ 211,561

XML

Acquisitions and Divestiture (Details) $ in Thousands			3 Months Ended			9 Months Ended
	Jul. 25, 2023 USD ($)	Jun. 28, 2021 USD ($)	Oct. 01, 2023 USD ($)	Dec. 31, 2022 USD ($) payment	Sep. 25, 2022 USD ($)	Oct. 01, 2023 USD ($)	Sep. 25, 2022 USD ($)	May 15, 2021 USD ($)
Business Acquisition [Line Items]
Net revenues			$ 746,389		$ 686,788	$ 2,200,580	$ 2,033,045
Standard Bariatrics
Business Acquisition [Line Items]
Consideration transferred				$ 173,000
Number of milestone payments | payment				3
Maximum additional payment upon completion of certain milestones				$ 130,000
Palette Life Sciences AB
Business Acquisition [Line Items]
Consideration transferred	$ 600,000
Maximum additional payment upon completion of certain milestones	$ 50,000
Disposal group, held-for-sale, not discontinued operations | Medline Manufacturing And Supply Transition Agreement
Business Acquisition [Line Items]
Net revenues			$ 21,700		$ 19,100	$ 62,700	$ 60,500
Respiratory Business | Disposal group, held-for-sale, not discontinued operations
Business Acquisition [Line Items]
Disposal group, including discontinued operation, consideration								$ 286,000
Disposal group, including discontinued operation, working capital								$ 12,000
Proceeds from divestiture of businesses		$ 259,000

XML

Restructuring and impairment charges - Charges recognized (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 01, 2023	Sep. 25, 2022	Oct. 01, 2023	Sep. 25, 2022
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 231	$ 628	$ 3,960	$ 1,453
Asset impairment charges			0	1,497
Restructuring and impairment charges	231	628	3,960	2,950
Termination Benefits
Restructuring Cost and Reserve [Line Items]
Restructuring charges	77	300	3,208	502
Asset impairment charges				0
Restructuring and impairment charges				502
Other restructuring costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	154	328	752	951
Asset impairment charges				1,497
Restructuring and impairment charges				2,448
2023 Footprint Realignment Plan
Restructuring Cost and Reserve [Line Items]
Restructuring charges	1,296		1,296
2023 Footprint Realignment Plan | Termination Benefits
Restructuring Cost and Reserve [Line Items]
Restructuring charges	1,296		1,296
2023 Footprint Realignment Plan | Other restructuring costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	0		0
2022 Restructuring Plan
Restructuring Cost and Reserve [Line Items]
Restructuring charges	346		3,674
2022 Restructuring Plan | Termination Benefits
Restructuring Cost and Reserve [Line Items]
Restructuring charges	244		3,361
2022 Restructuring Plan | Other restructuring costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	102		313
Respiratory divestiture plan
Restructuring Cost and Reserve [Line Items]
Restructuring charges	(846)	145	(579)	425
Respiratory divestiture plan | Termination Benefits
Restructuring Cost and Reserve [Line Items]
Restructuring charges	(851)	123	(596)	358
Respiratory divestiture plan | Other restructuring costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	5	22	17	67
2019 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Restructuring charges		(34)		(1,059)
2019 Footprint realignment plan | Termination Benefits
Restructuring Cost and Reserve [Line Items]
Restructuring charges		(50)		(1,120)
2019 Footprint realignment plan | Other restructuring costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges		16		61
2018 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Restructuring charges		455		1,061
2018 Footprint realignment plan | Termination Benefits
Restructuring Cost and Reserve [Line Items]
Restructuring charges		203		514
2018 Footprint realignment plan | Other restructuring costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges		252		547
Other restructuring programs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	(565)	62	(431)	1,026
Other restructuring programs | Termination Benefits
Restructuring Cost and Reserve [Line Items]
Restructuring charges	(612)	24	(853)	750
Other restructuring programs | Other restructuring costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 47	$ 38	$ 422	$ 276

XML

Restructuring and impairment charges - Expected costs to be incurred (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 01, 2023	Sep. 25, 2022	Oct. 01, 2023	Sep. 25, 2022
2023 Footprint Realignment Plan
Restructuring Cost and Reserve [Line Items]
Restructuring reserve	$ 1.3		$ 1.3
2023 Footprint Realignment Plan | Minimum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	11.0		11.0
Restructuring and Related Cost, Expected Cash Outlays	2.0		2.0
2023 Footprint Realignment Plan | Maximum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	15.0		15.0
Restructuring and Related Cost, Expected Cash Outlays	3.0		3.0
Respiratory divestiture plan
Restructuring Cost and Reserve [Line Items]
Restructuring expenses	1.6	$ 2.1	5.6	$ 6.5
Aggregate restructuring charges			2.7
Restructuring costs			17.9
Restructuring reserve	2.5		2.5
Respiratory divestiture plan | Minimum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	22.0		22.0
Restructuring and Related Cost, Expected Cash Outlays	22.0		22.0
Respiratory divestiture plan | Maximum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	24.0		24.0
Restructuring and Related Cost, Expected Cash Outlays	24.0		24.0
Special Termination Benefit And Other Restructuring | 2023 Footprint Realignment Plan | Minimum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	4.0		4.0
Special Termination Benefit And Other Restructuring | 2023 Footprint Realignment Plan | Maximum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	6.0		6.0
Special Termination Benefit And Other Restructuring | Respiratory divestiture plan | Minimum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	3.0		3.0
Special Termination Benefit And Other Restructuring | Respiratory divestiture plan | Maximum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	3.0		3.0
Accelerated Depreciation And Other Costs | 2023 Footprint Realignment Plan | Minimum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	7.0		7.0
Accelerated Depreciation And Other Costs | 2023 Footprint Realignment Plan | Maximum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	9.0		9.0
Accelerated Depreciation And Other Costs | Respiratory divestiture plan | Minimum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	19.0		19.0
Accelerated Depreciation And Other Costs | Respiratory divestiture plan | Maximum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	$ 21.0		$ 21.0

XML

Inventories (Detail) - USD ($) $ in Thousands	Oct. 01, 2023	Dec. 31, 2022
Inventory Disclosure [Abstract]
Raw materials	$ 186,216	$ 186,641
Work-in-process	111,371	98,993
Finished goods	327,488	292,873
Inventories	$ 625,075	$ 578,507

XML

Goodwill and other intangible assets, net - Changes in carrying amount of goodwill, by reporting segment (Details) $ in Thousands	9 Months Ended
	Oct. 01, 2023 USD ($)
Goodwill [Roll Forward]
Goodwill, beginning balance	$ 2,536,730
Currency translation adjustment	(8,425)
Goodwill, ending balance	2,528,305
Americas
Goodwill [Roll Forward]
Goodwill, beginning balance	1,731,093
Currency translation adjustment	2,608
Goodwill, ending balance	1,733,701
EMEA
Goodwill [Roll Forward]
Goodwill, beginning balance	468,524
Currency translation adjustment	(4,011)
Goodwill, ending balance	464,513
Asia
Goodwill [Roll Forward]
Goodwill, beginning balance	225,103
Currency translation adjustment	(7,022)
Goodwill, ending balance	218,081
OEM
Goodwill [Roll Forward]
Goodwill, beginning balance	112,010
Currency translation adjustment	0
Goodwill, ending balance	$ 112,010

XML

Goodwill and other intangible assets, net - Components of intangible assets (Details) - USD ($) $ in Thousands	Oct. 01, 2023	Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 3,560,803	$ 3,563,536
Accumulated Amortization	(1,380,264)	(1,257,371)
In-process research and development
Finite-Lived Intangible Assets [Line Items]
Indefinite-lived intangible assets	26,979	27,075
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets	1,326,706	1,328,539
Accumulated Amortization	(542,216)	(497,335)
Intellectual property
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets	1,600,259	1,599,355
Accumulated Amortization	(714,308)	(646,643)
Distribution rights
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets	23,087	23,115
Accumulated Amortization	(21,643)	(21,090)
Trade names
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets	562,461	564,023
Accumulated Amortization	(80,787)	(71,128)
Non-compete agreements
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets	21,311	21,429
Accumulated Amortization	$ (21,310)	$ (21,175)

XML

Borrowings - Components of long-term debt (Details) - USD ($) $ in Thousands	9 Months Ended
	Oct. 01, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Long-term debt, gross	$ 2,047,625	$ 1,723,250
Less: Unamortized debt issuance costs	(10,002)	(11,727)
Total long-term debt	2,037,623	1,711,523
Current borrowings	(87,500)	(87,500)
Long-term borrowings	$ 1,950,123	1,624,023
Revolving Credit Facility
Debt Instrument [Line Items]
Line of credit facility interest rate	6.67%
Long-term line of credit	$ 482,000	148,250
Term Loan
Debt Instrument [Line Items]
Line of credit facility interest rate	6.67%
Long-term line of credit	$ 490,625	500,000
Senior Notes | 4.625% Senior Notes due 2027
Debt Instrument [Line Items]
Debt instrument, stated interest rate	4.625%
Senior notes	$ 500,000	500,000
Senior Notes | 4.25% Senior Notes due 2028
Debt Instrument [Line Items]
Debt instrument, stated interest rate	4.25%
Senior notes	$ 500,000	500,000
Securitization program
Debt Instrument [Line Items]
Debt instrument, stated interest rate	6.29%
Securitization program	$ 75,000	$ 75,000

XML

Financial instruments - Additional information (Details) € in Millions		3 Months Ended		9 Months Ended
	Oct. 04, 2023 USD ($)	Oct. 01, 2023 USD ($)	Sep. 25, 2022 USD ($)	Oct. 01, 2023 USD ($)	Sep. 25, 2022 USD ($)	Oct. 02, 2023 USD ($) counterparty	Oct. 02, 2023 EUR (€) counterparty	Dec. 31, 2022 USD ($)	Dec. 31, 2019 USD ($) counterparty	Dec. 31, 2019 EUR (€) counterparty	Dec. 31, 2018 USD ($) counterparty	Dec. 31, 2018 EUR (€) counterparty
Derivatives Fair Value [Line Items]
Allowance for credit losses		$ 9,100,000		$ 9,100,000				$ 8,600,000
Allowance for credit losses, current		5,200,000		5,200,000				4,900,000
Cash flow hedging
Derivatives Fair Value [Line Items]
Ineffectiveness related to derivatives		0	$ 0
Foreign exchange contract | Not designated as hedging instrument
Derivatives Fair Value [Line Items]
Gains (losses) on derivatives		(1,000,000.0)	$ (1,000,000)	1,000,000.0	$ (4,200,000)
Total notional amount for all open foreign currency forward contracts		140,300,000		$ 140,300,000				152,900,000
Derivative, term of contract				12 months
Foreign exchange contract | Designated as hedging instrument | Cash flow hedging
Derivatives Fair Value [Line Items]
Total notional amount for all open foreign currency forward contracts		$ 238,100,000		$ 238,100,000				$ 184,800,000
Cross-currency interest rate swaps | Designated as hedging instrument
Derivatives Fair Value [Line Items]
Total notional amount for all open foreign currency forward contracts									$ 250,000,000	€ 219.2	$ 500,000,000	€ 433.9
Derivative, number of instruments held | counterparty									5	5	6	6
Derivative, fixed interest rate									4.88%	4.88%	4.63%	4.63%
Derivative, annual interest rate									2.46%	2.46%	1.94%	1.94%
Cross-currency interest rate swaps | Designated as hedging instrument | Subsequent event
Derivatives Fair Value [Line Items]
Total notional amount for all open foreign currency forward contracts						$ 500,000,000	€ 474.7
Derivative, number of instruments held | counterparty						6	6
Derivative, fixed interest rate						4.63%	4.63%
Derivative, annual interest rate						3.05%	3.05%
Proceeds from derivative instrument, investing activities	$ 43,000,000

XML

Financial instruments - Foreign exchange gains and losses recognized within AOCI and the interest benefit recognized within interest expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 01, 2023	Sep. 25, 2022	Oct. 01, 2023	Sep. 25, 2022
Derivative Instruments, Gain (Loss) [Line Items]
Foreign exchange gain	$ (29,417)	$ (55,194)	$ (13,368)	$ (123,576)
Interest benefit			15,459	15,677
Cross-currency interest rate swaps | Not designated as hedging instrument
Derivative Instruments, Gain (Loss) [Line Items]
Interest benefit	5,171	5,531	15,459	15,677
Cross-currency interest rate swaps | Cash flow hedging
Derivative Instruments, Gain (Loss) [Line Items]
Foreign exchange gain	$ 15,756	$ 42,189	$ 1,466	$ 68,643

XML

Financial instruments - Fair values of derivative instruments designated as hedging instruments (Details) - Cash flow hedging - USD ($) $ in Thousands	Oct. 01, 2023	Dec. 31, 2022
Derivatives Fair Value [Line Items]
Total asset derivatives	$ 71,946	$ 63,610
Total liability derivatives	3,241	1,460
Other assets
Derivatives Fair Value [Line Items]
Total asset derivatives	0	11,912
Foreign exchange contract | Prepaid expenses and other current assets
Derivatives Fair Value [Line Items]
Total asset derivatives	71,946	51,698
Foreign exchange contract | Other current liabilities
Derivatives Fair Value [Line Items]
Total liability derivatives	3,241	1,460
Foreign exchange contract | Designated as hedging instrument | Prepaid expenses and other current assets
Derivatives Fair Value [Line Items]
Total asset derivatives	4,288	3,154
Foreign exchange contract | Designated as hedging instrument | Other current liabilities
Derivatives Fair Value [Line Items]
Total liability derivatives	2,819	983
Foreign exchange contract | Not designated as hedging instrument | Prepaid expenses and other current assets
Derivatives Fair Value [Line Items]
Total asset derivatives	158	41
Foreign exchange contract | Not designated as hedging instrument | Other current liabilities
Derivatives Fair Value [Line Items]
Total liability derivatives	422	477
Cross-currency interest rate swaps | Not designated as hedging instrument | Prepaid expenses and other current assets
Derivatives Fair Value [Line Items]
Total asset derivatives	67,500	48,503
Cross-currency interest rate swaps | Not designated as hedging instrument | Other assets
Derivatives Fair Value [Line Items]
Total asset derivatives	$ 0	$ 11,912

XML

Fair value measurement - Financial assets and liabilities carried at fair value measured on recurring basis (Details) - USD ($) $ in Thousands	Oct. 01, 2023	Dec. 31, 2022
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Investments in marketable securities	$ 4,761	$ 10,097
Derivative assets	71,946	63,610
Derivative liabilities	3,241	1,460
Contingent consideration liabilities	18,302	44,022
Quoted prices in active markets (Level 1)
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Investments in marketable securities	4,761	10,097
Derivative assets	0	0
Derivative liabilities	0	0
Contingent consideration liabilities	0	0
Significant other observable Inputs (Level 2)
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Investments in marketable securities	0	0
Derivative assets	71,946	63,610
Derivative liabilities	3,241	1,460
Contingent consideration liabilities	0	0
Significant unobservable Inputs (Level 3)
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Investments in marketable securities	0	0
Derivative assets	0	0
Derivative liabilities	0	0
Contingent consideration liabilities	$ 18,302	$ 44,022

XML

Fair value measurement - Valuation technique and inputs used in determining the fair value of contingent consideration (Details)	Oct. 01, 2023
Revenue-based Payment | Monte Carlo simulation | Measurement Input, Revenue Volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Business combination, contingent consideration, liability, measurement input	0.306

XML

Fair value measurement - Reconciliation of changes in financial liabilities measured on recurring basis (Details) $ in Thousands	9 Months Ended
	Oct. 01, 2023 USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 44,022
Payments	(1,238)
Revaluations	(24,482)
Ending balance	$ 18,302

XML

Shareholders' equity - Reconciliation of basic to diluted weighted average common shares outstanding (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Oct. 01, 2023	Sep. 25, 2022	Oct. 01, 2023	Sep. 25, 2022
Equity [Abstract]
Basic (in shares)	46,992	46,906	46,974	46,894
Dilutive effect of share-based awards (in shares)	307	357	330	443
Diluted (in shares)	47,299	47,263	47,304	47,337

XML

Shareholders' equity - Additional information (Details) - shares shares in Millions	3 Months Ended		9 Months Ended
	Oct. 01, 2023	Sep. 25, 2022	Oct. 01, 2023	Sep. 25, 2022
Equity [Abstract]
Weighted average antidilutive shares which were not included in the calculation of earnings per share	0.8	0.7	0.7	0.5

XML

Shareholders' equity - Change in accumulated other comprehensive income, net of tax (Details) - USD ($) $ in Thousands	9 Months Ended
	Oct. 01, 2023	Sep. 25, 2022
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance	$ 4,021,968	$ 3,754,748
Other comprehensive income (loss) before reclassifications	(4,335)	(114,725)
Amounts reclassified from accumulated other comprehensive (loss) income	(4,293)	2,492
Net current-period other comprehensive income (loss)	(8,628)	(112,233)
Ending balance	4,314,048	3,895,161
Cash Flow Hedges
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance	4,931	1,081
Other comprehensive income (loss) before reclassifications	9,109	6,871
Amounts reclassified from accumulated other comprehensive (loss) income	(8,320)	(1,335)
Net current-period other comprehensive income (loss)	789	5,536
Ending balance	5,720	6,617
Pension and Other Postretirement Benefit Plans
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance	(135,799)	(138,290)
Other comprehensive income (loss) before reclassifications	(76)	1,980
Amounts reclassified from accumulated other comprehensive (loss) income	4,027	3,827
Net current-period other comprehensive income (loss)	3,951	5,807
Ending balance	(131,848)	(132,483)
Foreign Currency Translation Adjustment
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance	(272,654)	(209,750)
Other comprehensive income (loss) before reclassifications	(13,368)	(123,576)
Amounts reclassified from accumulated other comprehensive (loss) income	0	0
Net current-period other comprehensive income (loss)	(13,368)	(123,576)
Ending balance	(286,022)	(333,326)
Accumulated Other Comprehensive (Loss) Income
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance	(403,522)	(346,959)
Ending balance	$ (412,150)	$ (459,192)

XML

Shareholders' equity - Accumulated other comprehensive income into income expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 01, 2023	Sep. 25, 2022	Oct. 01, 2023	Sep. 25, 2022
Accumulated Other Comprehensive Income (Loss) [Line Items]
Cost of goods sold	$ 330,078	$ 312,833	$ 985,066	$ 924,024
Total before tax	149,605	119,196	374,040	336,503
(Benefit) tax	(11,935)	(17,315)	(47,651)	(51,700)
Income from continuing operations	137,670	101,881	326,389	284,803
Reclassification out of accumulated other comprehensive income
Accumulated Other Comprehensive Income (Loss) [Line Items]
Total reclassifications, net of tax	(2,234)	(376)	(4,293)	2,492
Reclassification out of accumulated other comprehensive income | Actuarial losses
Accumulated Other Comprehensive Income (Loss) [Line Items]
Total before tax	1,851	1,758	5,986	5,747
Reclassification out of accumulated other comprehensive income | Prior-service costs
Accumulated Other Comprehensive Income (Loss) [Line Items]
Total before tax	(252)	(252)	(756)	(756)
Reclassification out of accumulated other comprehensive income | Pension and Other Postretirement Benefits Plans
Accumulated Other Comprehensive Income (Loss) [Line Items]
Total before tax	1,599	1,506	5,230	4,991
(Benefit) tax	(368)	(352)	(1,203)	(1,164)
Income from continuing operations	1,231	1,154	4,027	3,827
Reclassification out of accumulated other comprehensive income | Foreign exchange contract | Cash Flow Hedges
Accumulated Other Comprehensive Income (Loss) [Line Items]
Cost of goods sold	(3,499)	(1,614)	(8,734)	(1,445)
Total before tax	(3,499)	(1,614)	(8,734)	(1,445)
(Benefit) tax	34	84	414	110
Income from continuing operations	$ (3,465)	$ (1,530)	$ (8,320)	$ (1,335)

XML

Taxes on income from continuing operations (Details)	3 Months Ended		9 Months Ended
	Oct. 01, 2023	Sep. 25, 2022	Oct. 01, 2023	Sep. 25, 2022
Income Tax Disclosure [Abstract]
Effective income tax rate	8.00%	14.50%	12.70%	15.40%

XML

Commitments and contingent liabilities (Detail) $ in Millions	9 Months Ended
	Oct. 01, 2023 USD ($)
Loss Contingencies [Line Items]
Estimated litigation liability	$ 0.6
Italian Parliament Legislation
Loss Contingencies [Line Items]
Loss contingency accrual	12.9
Loss contingency, loss in period	2.2
Loss contingency, estimate of possible loss	$ 18.6
Minimum
Loss Contingencies [Line Items]
Estimated time frame over which accrued amounts may be paid out	10 years
Maximum
Loss Contingencies [Line Items]
Estimated time frame over which accrued amounts may be paid out	15 years
Accrued liabilities
Loss Contingencies [Line Items]
Accrual for environmental loss contingencies	$ 2.5
Other liability
Loss Contingencies [Line Items]
Accrual for environmental loss contingencies	$ 4.1

XML

Segment information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 01, 2023	Sep. 25, 2022	Oct. 01, 2023	Sep. 25, 2022
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues	$ 746,389	$ 686,788	$ 2,200,580	$ 2,033,045
Operating profit	165,310	132,445	423,845	371,138
Operating segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	193,685	155,975	522,438	456,832
Unallocated expenses
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	(28,375)	(23,530)	(98,593)	(85,694)
Americas
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues	428,206	405,038	1,264,714	1,195,739
Americas | Operating segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	126,340	107,180	341,261	318,548
EMEA
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues	142,723	128,437	433,872	410,535
EMEA | Operating segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	17,876	7,472	43,744	29,291
Asia
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues	93,151	82,025	258,560	227,824
Asia | Operating segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	25,978	22,885	70,126	61,796
OEM
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues	82,309	71,288	243,434	198,947
OEM | Operating segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	$ 23,491	$ 18,438	$ 67,307	$ 47,197